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ABSTRACT 
 
Pannexins are newly discovered proteins that were first discovered by Panchin in 2000. 
The pannexin family has three isomers, i.e. pannexin-1, pannexin-2, and pannexin-3. 
In 2011, Billaud et al suggested that pannexin1 channels contribute to the spread of 
vasoconstriction after activation of α1D-adrenoceptors present on the surface of 
vascular smooth muscle cell (VSMCs) of thoracodorsal resistance arteries (TDA) 
isolated from mice. Phenylephrine acting upon the α1D-adrenoceptors activated 
pannexin1 channels present in the cell to release ATP, which in turn activated P2Y 
receptors on neighbouring cells to produce a co-ordinated contractile response. This 
aim of this work was to further investigate the role of pannexin in the regulation of 
contractile responses in the vasculature. To this end, the present study examined the 
presence and function of pannexins in the porcine splenic artery (PSA) and the rat 
aorta (RA), in which α1A- and α1D-adrenoceptors are present respectively. The role of 
pannexin channels and ATP (via activation of P2 purinoceptors) in the response to 
exogenous NA-induced contractile responses in the PSA and the RA were 
investigated, as were responses to sympathetic nerve activation in the PSA. The 
involvement of pannexin channels was studied using several pannexin inhibitors, i.e. 
mefloquine (a non-selective pannexin inhibitor), probenecid (a selective pannexin1 
inhibitor at low concentrations), carbenoxolone (a selective pannexin1 inhibitor) and 
                                                                     xii 
 
Brilliant Blue FCF (a selective pannexin1 inhibitor). Additionally, the involvement of 
ATP in NA-induced responses was examined using P2 purinoceptor antagonists 
(PPADS, suramin and NF449). Further experiments examined the role of pannexins 
in contributing to endothelium-dependent responses in a large vessel i.e. the porcine 
coronary artery (PCA). 
The results showed that both pannexin1 and pannexin2 are present in the PSA and the 
RA. In the PSA, mefloquine and probenecid reduced the responses to both NA-
induced contractions and the frequency-dependent response curves generated to 
sympathetic nerve stimulation, whereas carbenoxolone, suramin and PPADS had no 
effect on responses to either exogenous NA or those caused by activating the 
sympathetic nerves. In the RA, mefloquine and probenecid reduced the response to 
NA-induced contractions, whereas BB-FCF had no effect. Purinoceptor antagonists 
(suramin, PPADs and NF449) had no effect on responses mediated by either α1A–
adrenoceptors in the PSA or α1D–adrenoceptors in the RA, arguing against the role of 
ATP (via activation of P2 receptors) in mediating NA-induced responses in either the 
PSA or the RA. Conflicting results were obtained, in some cases, upon the use of three 
different pannexin inhibitors. The most likely reason for this is that mefloquine 
demonstrated non-selective inhibitory actions on contractile responses since it was 
also shown to inhibit responses to KCl, 5-HT, U46619 (the thromboxane mimetic), 
and responses to re-addition of calcium to depolarised preparations, suggesting that it 
acts to block L-type Ca2+ currents. Both mefloquine and probenecid demonstrated non-
selective inhibitory effects when used at relatively high concentrations. Therefore, 
mefloquine and probenecid should only be used in low concentrations as pannexin1 
inhibitors. It has been suggested that pannexin proteins may be involved in mediating 
endothelium-derived hyperpolarizing factor (EDHF) responses (Gaynullina, 
                                                                     xiii 
 
Shestopalov et al 2015). Bradykinin (BK) was shown to induce relaxation in PCA and 
to a lesser extent in the PSA after inhibition of NO-synthase and cyclooxygenase. The 
evidence for the involvement of pannexin in mediating an EDHF response was limited 
in both the PSA and the PCA, since neither carbenoxolone nor probenecid had any 
effect. While mefloquine reduced EDH-mediated responses to bradykinin in the PCA, 
the questions about its selectivity make this observation difficult to interpret.  
The present work therefore provided some evidence for the involvement of pannexin 
channels in conducting responses to NA-induced α1-adrenoceptor-mediated 
vasoconstriction in blood vessels in PSA and the RA, although great care must be taken 
in interpreting this data on the basis of a lack of selectivity of the pharmacological 
agents currently available as pannexin inhibitors. In addition, there was no evidence 
that activation of α1-adrenoreceptors causes the release of ATP from inside cells to act 
as an intercellular messenger, leading to P2 receptor-mediated contractions.  
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Chapter 1  
1. Introduction 
1.1. Cardiovascular hemodynamics 
The cardiovascular system is designed to carry out a variety of functions to maintain 
whole body homeostasis. These functions include the transport of gases, nutrients and 
waste products, the transport of hormones, the regulation of pH and osmolality and the 
maintenance of body temperature (Seeley et al 2008). 
It is crucial that blood flow is able to meet the demands of different tissue under 
different metabolic conditions. To achieve this requirement, blood flow needs to be 
maintained appropriately, and the cardiovascular system has to provide continuous 
blood flow through the arteries and veins, driven by the pumping action of the heart.  
Systemic arteries carry oxygenated blood from the heart to the capillaries where gas, 
nutrient and waste exchange occurs. The deoxygenated blood is then returned to the 
heart via the veins, which can then be delivered to the pulmonary circulation. 
Deoxygenated blood enters the pulmonary arteries and is circulated around the lungs 
to permit gas exchange. Subsequently, the pulmonary veins return the re-oxygenated 
blood to the heart. 
Arteries and veins share a common structure in that they are comprised of three 
distinctive layers (Figure 1.1). The innermost layer (tunica intima) contains a single 
layer of endothelial cells. This layer appears flattened and smooth. Adjacent to the 
tunica intima is the tunica media which is a wall containing smooth muscle cells. At 
the edge of this layer lie the vascular sympathetic nerves (Rutishauser, 1994). The 
outer layer (tunica adventitia) contains collagen and elastin fibers, which provide the  
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arterial walls with strength and flexibility. Arteries have a much thicker tunica media 
and tunica adventitia than veins, allowing them to accommodate the high level of 
arterial blood pressure by providing extra strength and elasticity. The capillaries are 
the simplest among the blood vessels, and they contain just a single layer of endothelial 
cells surrounded by a basement membrane (Rutishauser, 1994). 
 
Figure 1.1 A diagram representing the comparison of blood vessels structure and 
functions. Adapted from Clancy & McVicar (2009).  
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1.2. Role of blood vessels in the regulation of systemic blood pressure 
Blood pressure is the hydrostatic force that the blood exerts against the wall of the 
vessel. The arterial blood pressure is determined by the multiple of cardiac output and 
total peripheral resistance. Cardiac output is determined by heart rate and stroke 
volume. The latter is largely determined by the amount of blood returning to the heart, 
and is influenced by the force of contraction of cardiac muscle cells. The blood in veins 
travels at lower velocity and pressure compared to that in arteries. To facilitate the 
flow of the low pressure blood in veins, the contraction of the skeletal muscles 
squeezes the veins to increase the blood flow through them. Importantly, the extent of 
vasoconstriction and vasodilation of veins will influence venous return, ultimately 
impacting on cardiac output and blood pressure (McGeown, 2002; Seeley et al 2008). 
The small arteries and arterioles are crucial in controlling peripheral resistance and 
hence in regulating blood pressure, thus the impedance offered by the arterioles 
induces the peripheral resistance and controls blood pressure. Vasoconstriction of 
arterioles increases peripheral resistance, whereas vasodilation reduces peripheral 
resistance and lowers blood pressure. This relationship has led to the primary focus of 
research on the cardiovascular system to principally assess arterial function. However, 
the blood vessel diameter of both arteries and veins is critical in regulating blood 
pressure. Several mechanisms are responsible for the control of vessel diameter 
including the sympathetic nervous system, circulating hormones such as those released 
by activation of the renin-angiotensin system and factors released from the vascular 
endothelium (Gordan et al 2015; Seeley et al 2008). A number of vasodilators are 
released from the endothelium as a result of physical stress or hormonal action. These 
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include prostacyclin, nitric oxide and endothelium-derived hyperpolarizing factor 
(EDHF), which cause relaxation of the vascular smooth muscle.  
 
1.3. Sympathetic nerves 
Sympathetic nerves store catecholamines in their terminal vesicles (Falck, 1962). The 
presence and distribution of sympathetic nerves has been demonstrated in different 
blood vessels in many species including terminal arterioles of the rat mesentery 
(Furness, 1973), monkey pulmonary arteries (El-Bermani, 1978), and rat superior 
mesenteric arteries and veins, where the adrenergic innervation was visualized by the 
Hillarp-Falck fluorescence technique, and by the immunohistochemical localization of 
immunoreactivity to tyrosine hydroxylase and dopamine-beta-hydroxylase. (Nilsson 
et al 1986). Furthermore, the retrograde fluorescent dye, fast blue, has also been used 
to identify the location of sympathetic neurons supplying mesenteric arteries of the rat 
(Sheppard, 1986). More recently the presence of dense sympathetic innervation in 
human mesenteric arteries and veins has been demonstrated using 
immunohistochemical staining coupled with electron microscopy (Birch et al 2008). 
 
1.4. Sympathetic neurotransmission  
Postganglionic sympathetic nerves activation produces biological effects via the 
release of neurotransmitters. Originally, it was thought that noradrenaline (NA) is the 
sole neurotransmitter released from sympathetic neurons, however, it was then 
reported that more than one neurotransmitter from the same neuron can also be 
released (Burnstock, 1976) (Figure 1.2). For example, adenosine triphosphate (ATP) 
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was implicated by Burnstock as a sympathetic neurotransmitter (Burnstock, 1972). In 
addition, it was shown that neuropeptide Y (NPY) is also released from the 
sympathetic nerves (Lundberg et al 1983). These discoveries prompted the 
development of the concept of co-transmission. Co-transmission is now a well-
established concept in the central and peripheral nervous systems. However, the 
physiological significance of co-transmission is still not fully clear. It has been 
proposed that co-transmission allows a synergistic relationship between various 
neurotransmitters; for instance, a synergistic relationship was reported between NA as 
the main transmitter and ATP as a co-transmitter in rat mesenteric artery smooth 
muscle cells, and it has been shown that ATP can cooperate with NA to cause smooth 
muscle contraction in a synergistic manner (Ralevic and Burnstock, 1990).  
It has also been shown that the release of cotransmitters can cause presynaptic 
neuromodulation and regulation of the release of the main transmitter. For instance, 
NPY inhibited the release of NA and ATP in the guinea-pig vas deferens (Ellis and 
Burnstock, 1990). In contrast, NPY enhanced the release of NA in rabbit blood vessels 
(Edvinsson et al 1984). Furthermore, it has been shown that NA release is favoured at 
higher impulse frequencies while NPY and ATP release is favoured at lower impulse 
frequencies of EFS in rat tail artery (Bradley et al 2003), which means that in response 
to different parameters of stimulation the presence of more than one neurotransmitter 
would allow different responses of nerves to take place. 
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Figure 1.2 Diagram shows the release of different neurotransmitters including 
noradrenaline (NA) and ATP from sympathetic nerves, and their effect on different 
receptors; α1- and P2X on the postsynaptic membrane to induce contraction. Adapted 
from  (Kennedy et al 2013). 
 
1.5. Noradrenaline 
As mentioned above, activation of sympathetic nerves releases a number of 
neurotransmitters including NA. The involvement of catecholamines was first 
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proposed by Gaddum and Kwiatkowski, (1939) when exogenous adrenaline induced 
a similar response to that induced by the active substances released by adrenergic 
nerves in perfused rabbit ear and frog heart (Gaddum and Kwiatkowski, 1939). 
Subsequently, biochemical studies revealed the presence of enzymes responsible for 
NA synthesis in chromaffin cells and neurons, and that chromaffin cells and neurons 
were capable of storing and releasing catecholamines (Blaschko, 1957). Further 
experiments showed that NA synthesis was initiated from tyrosine in the homogenates 
of sympathetic nerve tissue, indicating that tyrosine acts as the main precursor of NA 
synthesis (Goodall and Kirshner, 1958). Tyrosine is transported by noradrenaline 
carriers into the cytoplasm of adrenergic neurons where it is converted to dopa by the 
activity of tyrosine-3-monooxygenase. Subsequently, L-amino acid decarboxylase 
converts dopa to dopamine, and the latter is transported into sympathetic vesicles 
where it undergoes hydroxylation to form NA (Blaschko, 1957). The release of NA 
from its storage vesicles appears in a Ca2+ dependent manner which occurs following 
activation of the terminal nerve by an action potential. Direct evidence for the release 
of NA was initially shown using the measurement of tritium released from tissues 
preloaded with [3H] NA in rabbit main pulmonary artery (Su and Bevan, 1970). 
Furthermore, the release of endogenous NA from sympathetic nerves has been 
measured using high performance liquid chromatography in rat tail artery and in the 
rat mesenteric artery (Buchholz and Duckles, 1992; Ralevic and Kendall, 2002). The 
majority of evidence which showed that NA is the main sympathetic neurotransmitter 
in blood vessels was based on pharmacological studies. For instance, responses to 
sympathetic nerve stimulation were abolished by the α1-adrenoceptor antagonist 
prazosin, providing evidence that NA was the main neurotransmitter in guinea-pig, rat 
and rabbit small blood vessels (Angus et al 1988). 
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1.6. Adrenoceptors 
Originally, adrenoceptors were described as the hypothetical structures located near 
the muscle or gland cells affected by adrenaline (Dale, 1906). Then researchers 
recognised two different groups of adrenoceptors for which the endogenous ligands 
were catecholamines (Ahlquist 1948). They attributed the variation in tissues response 
to these two groups rather than variations of neurotransmitters. These two groups were 
classified as alpha (α) and beta (β) based on their pharmacological responses (Ahlquist 
1948); the discovery of dichloroisoprenaline, which was the first agent capable of 
antagonising β-adrenoceptor-mediated responses selectively, confirmed the existence 
of α and β subtypes (Powell and Slater, 1958). 
1.6.1. α-adrenoceptors 
There are two major classes of α-adrenoceptors. α1-adrenoceptors are activated by 
phenylephrine, methoxamine and blocked by prazosin, while α2-adrenoceptors are 
activated by UK-14,304 or BHT933 and blocked by BRL44408 (Alexander et al 
2009). The use of cloning methods has shown three further subtypes of α1-
adrenoceptors; α1A, α1B and α1D (Hieble et al 1995) and three subtypes of α2-
adrenoceptors; α2A, α2B and α2C (Kobilka et al 1987; Regan et al 1988; Lomasney et 
al 1990).  
α-adrenoceptors function 
α1-adrenoceptors couple to Gq/11 protein, activation of which results in stimulating 
phospholipase C enzyme which promotes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate producing inositol triphosphate (IP3) and diacyl glycerol (DAG). IP3 and 
DAG act as second messengers mediating intracellular Ca2+ release from intracellular 
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stores (Zhong and Minneman, 1999). Activation of α2-adrenoceptors, which are 
primarily coupled to Gi-protein, results in inhibiting adenylyl cyclase which induces a 
reduction in intracellular adenosine 3',5'-cyclic monophosphate (cyclic AMP) 
production (Bylund et al 1994; Wise et al 1997). 
In terms of their roles in the vasculature, postsynaptic α1-adrenoceptors have been 
primarily shown to mediate contractile responses to sympathetic nerve activation, 
which was demonstrated in a number of blood vessels in different species. For 
instance, electrically-evoked contractile responses were sensitive to α1-adrenoceptors 
antagonism in rabbit hindlimb (Madjar et al 1980), isolated pulmonary artery of the 
rabbit (MacLean et al 1993) and horse penile resistance arteries (Simonsen et al 1997). 
On the other hand, a role for α2-adrenoceptors in mediation of postjunctional responses 
to the α2-adrenoceptor agonist UK 14304 has been reported in small resistance vessels 
including human subcutaneous resistance vessels (Nielsen et al 1989). By contrast, in 
large arteries, activation of α2-adrenoceptors required experimental manipulation; 
increasing of perfusion pressure by arginine vasopressin in the isolated vascular bed 
of the rat tail (Templeton et al 1989), or the presence of an unrelated vasoconstrictor 
such as angiotensin II in rabbit isolated distal saphenous artery (Dunn et al 1989) and 
the presence of U46619 and forskolin in porcine isolated ear artery (Roberts et al 
1998).  
In human blood vessels, in vivo studies showed the expression of postjunctional α1- 
and α2-adrenoceptors by measuring the effect on forearm blood flow induced by intra-
arterial infusions of selective α1- and α2-adrenoceptor agonists and antagonists (Jie et 
al 1984). Presynaptic α2-adrenoceptors were demonstrated to modulate NA release 
from sympathetic nerve endings via a negative feedback mechanism in humans (Jie et 
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al 1987). The involvement of both postjunctional α1- and α2-adrenoceptors in the 
mediation of the electrically-evoked vasoconstrictor responses in human 
gastroepiploic artery has been reported previousely (Fukui et al 2005). 
 
1.6.2. β-adrenoceptors 
Two subtypes of β-adrenoceptors were originally identified on the basis of different 
potency to agonists; the β1-adrenoceptor (equally sensitivity to both NA and adrenaline 
and dominance) and the β2-adrenoceptor (with less sensitivity to NA) (Lands et al 
1967). Subsequently, studies on tissues expressing β-adrenoceptors showed that some 
of these receptors are unresponsive to β1- and β2- agonists. This raised the possibility 
of the existence of a third β-adrenoceptor subtype. The use of cloning confirmed the 
presence of the human β1-adrenoceptor (Frielle et al 1987), mammalian β2-
adrenoceptor (Dixon et al 1986) and human β3-adrenoceptor (Emorine et al 1989). 
Thus, β-adrenoceptors are classified into three types; β1-adrenoceptors responsible for 
the regulation of contractility and heart rate, β2-adrenoceptors mediating vasodilatation 
evoked by sympathomimetic agonists and β3-adrenoceptors which are predominant in 
adipose tissue and regulate biolysis (Guimaraes and Moura, 2001; Alexander et al 
2009). 
 
 
                                                                     11 
 
1.7. Adenosine triphosphate (ATP) as a signalling molecule 
1.7.1. ATP and purinergic receptors 
Early reports showed that ATP is the source of energy for the cell and a signalling 
molecule (Drury, 1936). Subsequent studies observed that ATP acted as a signalling 
molecule on skeletal muscle (Buchthal and Folkow 1948) and the uterus (Mihich et al 
1954). Burnstock and colleagues found stronger confirmation that reinforced the 
signalling action of ATP when they observed that ATP relaxed intestinal smooth 
muscle (Burnstock et al 1970) and stimulated smooth muscle of the bladder 
(Burnstock et al 1972). Following publication of these studies, Burnstock created the 
phrase purinergic signalling to refer to the signalling action mediated by ATP. If ATP 
is a ligand, it must bind to a receptor (termed a purinergic receptor) in order to produce 
a response. The classification of purinergic receptors is P1 receptors (adenosine-
binding receptors) and P2 receptors (ATP-binding receptors) (Burnstock 1978). P2 
receptors are divided into the ionotropic P2X receptors and the metabotropic P2Y 
receptors (Dubyak 1991). The different P2 receptors are expressed in various cell types 
throughout the body, including in brain stem neurons (King et al 2000) and in 
cardiovascular system (Muraki et al, 1998). 
1.7.2. ATP release and degradation pathways 
ATP release has been observed for decades in multiple systems including the nervous 
system (Holton 1959). ATP release was first thought to only occur in damaged cells 
(Burnstock, 2006b), but was later found to occur in healthy cells such as erythrocytes 
(Bergfeld and Forrester, 1992). ATP release is classified as lytic (from cell lysis), 
vesicular, or non-vesicular (Burnstock 2006a). Vesicular ATP release has been 
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determined to occur through exocytosis (Maroto and Hamill 2001). However, the 
identity of the main non-vesicular ATP release protein is still unclear. Some of the 
main proteins proposed to mediate the non-vesicular ATP release include: the cystic 
fibrosis transmembrane conductance regulator (CFTR) (Reisin et al 1994), ATP-
binding cassette (ABC) transporters (Roman et al 1997), a volume-regulated anion 
channel (VRAC) (Hisadome et al 2002), a maxi-anion channel (Sabirov and Okada 
2004), connexin gap junction hemichannels (connexons) (Cotrina et al 1998), the 
P2X7 receptor (Suadicani et al 2006), and pannexin 1 (Bao et al 2004). 
The release of ATP following depolarizing stimuli has been demonstrated in various 
blood vessels including rabbit pulmonary artery and rat caudal artery (Westfall et al 
1987, Takeuchi et al 1994). In addition, ATP release has been reported in cultured 
sympathetic nerve terminals where tetrodotoxin (neurone toxin) inhibited this release 
(Richardson and Brown, 1987, Von Kügelgen et al 1994). The release of ATP 
following nerve stimulation has also been shown to be a Ca2+-dependent process 
(Brock and Cunnane, 1999).  
Once ATP is released into the extracellular fluid, it is regulated by cell surface located 
enzymes namely ectonucleotidases. Ectonucleotidases are capable of hydrolyzing 
ATP to adenosine-5’-diphosphate (ADP), adenosine-5’-monophosphate (AMP) and 
adenosine (Burnstock, 2011, Zimmermann, 2006). However, stimulation of 
sympathetic nerves innervating the guinea-pig vas deferens was shown to release not 
only neuronal ATP, but also soluble nucleotidases which results in breaking down 
extracellular ATP, ADP, and AMP into adenosine (Kennedy et al 1997, Todorov et al 
1997). 
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1.7.3. ATP as an extracellular neurotransmitter 
In 1960 Burnstock and his colleagues observed inhibitory junction potentials, 
hyperpolarisations of smooth muscle produced by stimulation of inhibitory nerves, 
from intestinal smooth muscle as a result of the stimulation of noradrenergic 
noncholinergic (NANC) nerves. The nature of the transmitter which was involved this 
inhibitory effect remained unclear (Burnstock and Prosser, 1960). It was not until 1970 
that Burnstock and other co-workers uncovered the nature of the transmitter which was 
responsible for this inhibition. They investigated the vagal noradrenergic inhibitory 
responses of guinea-pig and they showed the presence of ATP in the vascular 
secretions. Thus, they concluded that ATP was the transmitter substance released by 
noradrenergic inhibitory nerves (Burnstock et al 1970). Furthermore, it was 
demonstrated that ATP has postjunctional effects on the smooth muscle of vas deferens 
of guinea-pig (Westfall et al 1978). Subsequent studies showed that neurogenic 
responses in the vas deferens of the guinea pig were blocked by an ATP receptor 
antagonist arylazido aminopropanol ATP (ANAPP3) (Fedan et al 1981). Moreover, 
an ATP receptor desensitizing agent, α,β-methyleneATP, abolished the inhibitory 
junction potentials obtained to EFS in guinea-pig vas deferens (Sneddon and 
Burnstock, 1984). In blood vessels, it was demonstrated that exogenous ATP evoked 
vasoconstriction followed by vasorelaxation in isolated rabbit portal vein (Kennedy 
and Burnstock, 1985). These findings supported the concept of ATP being a 
cotransmitter with noradrenaline in sympathetic neurones (Lagercrantz, 1971).  
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1.8. Purinoceptors 
In 1978, Burnstock introduced the first classification of the purinergic receptors 
(Burnstock, 1978). The nomenclature used by Burnstock divided these receptors into 
P1 and P2 purinoceptors. P1 receptors were reported to be much more responsive to 
the adenosine and AMP than to ATP and ADP, while P2 receptors were proposed to 
be much more responsive to ATP and ADP than to AMP and adenosine (Burnstock, 
1978). In 1985, a report suggested a pharmacological basis for discriminating two 
types of P2 receptors (P2X and P2Y receptors) (Burnstock & Kennedy, 1985). 
According to this classification, P2X receptors were most potently activated by α,β-
methyleneATP, while 2-methylthio-ATP (2-MeSATP) was at that time the most 
potent agonist at P2Y receptors. In 1989, it was observed that P2Y receptors responded 
to pyrimidine nucleotides as well as to purine nucleotides (Seifert and Schultz 1989). 
The current classification was first proposed in 1994; it divides purinergic receptors 
on the basis of molecular structure and transduction mechanisms (Abbracchio and 
Burnstock 1994). Hence, purinergic receptors can be sub-divided into two major 
families: a P2X receptor family of ligand-gated ion channel receptors, which are 
activated by ATP and its analogues, in addition to a P2Y receptor family of G protein-
coupled receptors (Abbracchio and Burnstock 1994). P2Y receptors are activated by 
ATP, ADP, uridine-5’-triphosphate (UTP), uridine-5’-diphosphate (UDP) and UDP-
sugars and their analogues. 
Significant developments in molecular, biochemical and pharmacological techniques 
have led to the further subdivision of purinoceptors. Thus at present P2 receptors are 
divided into two groups, P2X and P2Y. P2X receptors are divided into seven suptypes; 
P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7 receptors. The P2Y family is 
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divided into eight mammalian subtypes; P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, 
P2Y13 and P2Y14 receptors. P1 receptors are subdivided into A1, A2A, A2B, and A3 
receptors (Ralevic and Burnstock, 1998; Alexander et al 2009). 
 
1.8.1. P2X receptors 
P2X receptors are ligand-gated ion channels, activation of which results in Ca2+ influx 
in addition to monovalent cations such as Na+ and K+, and small organic cations 
(Benham and Tsien, 1987; Valera et al 1994). The structure of P2X receptors is shown 
in Figure 1.3, P2X subunits have two hydrophobic, transmembrane spanning regions 
which cross the plasma membrane; they are connected by an extracellular loop, which 
contains the ATP binding site (Kennedy et al 2013). Using radioligand assay with 
[3H]α,β-methyleneATP, the expression of P2X receptors on vascular smooth muscle 
of mesenteric, renal, and pulmonary arteries as well as in the aorta and on rat veins 
was confirmed (Bo and Burnstock, 1993; Hansen et al 1999).  
In response to ATP, P2X receptors mediate vasoconstriction (Ralevic and Burnstock, 
1998). In the vasculature it has been shown that P2X receptor activation mediates 
vasoconstriction in a number of blood vessels including rabbit basilar artery, rat 
pulmonary vessels and renal arteries (Lee et al 1976; Inscho et al 1994; Liu et al 1989). 
Furthermore, it was shown that the postjunctional responses of sympathetic nerve 
stimulation were solely mediated by the activation of P2X receptors in submucosal 
arterioles of the guinea-pig (Evans and Surprenant, 1992). Also, in P2X-receptor 
deficient mice, the P2X receptor agonist α,β-methyleneATP failed to induce any 
response indicating that the response-mediated by α,β-methyleneATP was due to 
activation of  P2X receptors (Lamont et al 2006). In P2X1 receptor knockout mice, 
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vasoconstrictions to nerve stimulation were reduced by ~50% and these responses 
were unaffected by the P2 receptor antagonist PPADS (which is normally reduced the 
responses by about 50% in wild type arteries) (Vial, 2002). 
In a study characterizing P2X receptor immunoreactivity, it was shown that P2X1 
receptors were expressed in a number of blood vessels including femoral, pulmonary, 
cerebral and renal arteries of the rat (Lewis and Evans, 2001). However, the presence 
of other P2X receptors on endothelium has also been described such as P2X2 receptors 
on small cerebral arteries of the rat (Loesch and Burnstock, 2000). Furthermore, P2X4 
and P2X5 receptors are expressed on human endothelial cell monolayers where ATP 
was shown to be released constitutively and exclusively across the membrane under 
basal conditions to activate the purinergic receptors and induce ATP receptor-triggered 
signal transduction. Hence, it has been suggested that these receptors are involved in 
self-regulation of endothelial function and therefore modulating vascular tone 
(Schwiebert et al 2002). P2X4 and P2X6 receptors were also found on human 
endothelial cells where they have been shown to play a role in cell permeability and 
adhesion through their colocalisation with the cell adhesion molecule VE-cadherin 
(Glass et al 2002). 
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Figure 1.3 Schematic representation of a typical P2X7 receptor subunit: It consists of 
intracellular N-terminal and C-terminal domain and two transmembrane domains 
which are connected through an extracellular loop. Taken from Tewari et al. 2015.  
 
1.8.2. P2Y receptors 
P2Y receptors are G-protein-coupled receptors (GPCRs). Their structure is common 
to that of other G protein-coupled receptors. They contain seven α-helical 
transmembrane domains of hydrophobic amino acids; these domains are connected via 
three extracellular and three intracellular loops, with an extracellular N-terminus and 
an intracellular C-terminus (Jacobson et al 2012) (Figure 1.4). On the basis of the 
action of their endogenous agonists, P2Y receptors can be divided into adenine 
nucleotide-preferring receptors (P2Y1, P2Y11, P2Y12 and P2Y13) responsive to ATP or 
ADP, and uracil nucleotide-preferring receptors (P2Y2, P2Y4, P2Y6 and P2Y14) 
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responsive to UDP, UTP and UDP-sugars (von Kugelgen, 2006; Alexander et al 
2009). Furthermore, according to their G protein coupling and second messenger 
systems, P2Y receptors can also be subdivided into two groups. One group includes 
P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptors which are primarily coupled to the Gq/11 
family of G proteins to activate phospholipase C, resulting in elevation of intracellular 
calcium levels. The other group includes P2Y12, P2Y13 and P2Y14 receptors, which are 
primarily coupled Gi/o family of G proteins to inhibit adenylyl cyclase, resulting in a 
reduced accumulation of cyclic AMP (Ralevic, 2009).  
 
P2Y receptors can be expressed on the endothelial cells, for instance, in human blood 
vessels immunohistochemical staining showed the presence of P2Y2 receptors on the 
endothelium of some human blood vessels including the internal mammary artery, 
radial artery and saphenous vein (Ray et al 2002). Furthermore, immunoreactivity for 
P2Y1, P2Y2 and P2Y6 receptors has been shown on the vascular endothelium of human 
umbilical vein (Wang et al 2002). It seems that the most dominant functional P2Y 
receptors which are expressed on vascular endothelial cells are P2Y1 and P2Y2 
receptors and they act as sensors for shear stress and hypoxia in response to locally 
released purines (Ralevic, 2009). However, P2Y receptors can also be found on 
vascular smooth muscle. For example, immunoreactivity to P2Y1, P2Y2, P2Y4 and 
P2Y6 receptors was shown on circular and longitudinal smooth muscle of human long 
saphenous veins (Metcalfe et al 2007). Functional studies have shown evidence for the 
involvement of P2Y2 and P2Y6 in regulating the blood vessels contractility. For 
example, P2Y2 receptors have been shown to be involved in the mediation of 
contractile responses to uracil nucleotides in human coronary arteries (Malmsjo et al 
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2000). In addition, P2Y2 and P2Y6 receptors have also been shown to be involved in 
the mediation of contractile responses to uracil nucleotides in rat cerebral 
microvasculature (Lewis et al 2001). 
 
   
Figure 1.4 Schematic representation of the P2Y receptor subfamily. They have seven 
putative transmembrane domains (I-VII). These domains are linked via three 
extracellular and three intracellular hydrophilic loops. The arrangement of the 
transmembrane regions forms a pocket for the ligand binding site. Figure is taken from 
(Lazarowski and Boucher 2001). 
 
1.9. Vascular endothelium 
The endothelium forms an important part of the vasculature and is involved in 
controlling the blood flow via the complementary actions of endothelial cell-derived 
vasoactive factors including nitric oxide (NO) and endothelium-derived 
hyperpolarizing factors (EDHFs), which play an important role in endothelium-
mediated vasorelaxation in many vessels by inducing a vasodilatation of the 
underlying smooth muscle. 
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1.9.1. Nitric oxide  
In 1980, Furchgott and Zawadziki proposed that intact endothelial cells were required 
for acetylcholine to induce arterial smooth muscle cell relaxation by releasing a factor, 
which they termed endothelium derived relaxation factor “EDRF”. They ruled out the 
possibility that the EDRF was bradykinin , prostacyclin, cyclic AMP or adenosine but 
they were unable to positively identify it (Furchgott and Zawadzki 1980). 
Subsequent studies led to the identification of some factors involved in EDRF release 
from the vascular endothelial cells including nitric oxide (NO) (SoRelle, 1998). It is 
now known that NO is released from both endothelial cells and neurons and directly 
modulates smooth muscle tone (Förstermann et al 1991). It is a small hydrophobic gas 
which is able to diffuse across cell membranes without the aid of channels or receptors, 
and its action can be regulated by its concentration, proximity to the target cell and its 
short half-life. In blood vessels, NO diffuses from the endothelium to the smooth 
muscle cells and targets the haem moiety of soluble guanylate cyclase to catalyse the 
formation of cyclic guanine monophosphate (cGMP) from guanine triphosphate 
(GTP). This stimulates several protein kinases and lowers cytosolic calcium, thus 
initiating vascular smooth muscle relaxation (Buhimschi et al 1998).  
NO is synthesised by nitric oxide synthases (NOS) (Hensley et al 1997). There are 
three major isoforms of NOS (neuronal NOS (nNOS or Type I), inducible NOS (iNOS 
or type II) and endothelial NOS (eNOS or type III). All of these isoforms have been 
cloned and purified, and they differ in the factors that regulate them and in their 
subcellular location (Alderton et al 2001). 
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Neuronal NOS (nNOS) 
nNOS is a Ca2+-dependent enzyme that generates NO in both the central and peripheral 
nervous system (Garthwaite, 1995; Bredt et al 1990). Following nerve stimulation, 
nNOS has been shown to cause vasodilation in several isolated blood vessels including 
canine, monkey and human cerebral arteries (Toda and Okamura, 1990). 
Inducible NOS (iNOS) 
iNOS is not usually expressed in healthy vascular cells and therefore does not 
contribute to the regulation of basal NO levels and vascular tone. However, in 
conditions of infection or inflammation, bacterial lipopolysaccharides or pro-
inflammatory cytokines induce the transcription of iNOS (Vallance, 2003). During 
these conditions, increased activity of iNOS in arteries induces decreased systemic 
vascular resistance and hypotension (Annane et al 2000). 
Endothelial NOS (eNOS) 
eNOS was described in endothelial cells and it is associated with endothelial cell 
membranes (Buhimschi et al 1998). eNOS is stimulated by a variety of stimuli 
including acetylcholine, bradykinin , serotonin, ATP and shear stress to catalyse the 
reaction of L-arginine, NADPH and oxygen to citrulline, NADP and NO in a 
Ca2+/calmodulin dependent manner (Alderton et al 2001; Arnal et al 1999). 
The synthesis of NO synthase inhibitors such as NG -Monomethyl-L-arginine (L-
NMMA) and NG-Nitro-L-arginine Methyl Ester (L-NAME) has proved crucial in 
investigating the physiological importance of NO and its contribution to vascular 
dysfunction: NOS inhibitors compete with L-arginine for the eNOS binding site. It has 
been demonstrated that intravenous administration of L-NAME caused a dose–
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dependent pressor response in rats (Gardiner et al 1990). Vasoconstrictor effects were 
most profound in the mesenteric vascular bed. The effect of L-NAME could be 
reduced or reversed by L-arginine addition. Gardiner et al (1990) also showed that oral 
administration of L-NAME caused a more prolonged hypertension (Gardiner at al., 
1990). 
Vallance et al (1989) demonstrated that endothelium-derived NO was continuously 
released in the forearm arterial bed and therefore contributed to basal blood flow. They 
also showed that L-NMMA inhibited acetycholine-induced relaxation in single dorsal 
hand veins; this effect was reversed by treatment with L-arginine (Vallance et al 1989). 
Subsequently, NO release has been shown to occur in many other blood vessels 
including large arteries such as the rat aorta (Shimokawa et al 1996) and brachial 
arteries (Urakami-Harasawa et al 1997), as well as in smaller arteries including distal 
arteries in the rat mesenteric bed (Shimokawa et al 1996) and small branch arteries in 
the rabbit ear (Berman et al 2002). The majority of experiments have found that NO 
has a predominant effect on larger arteries than smaller arteries. NO release has also 
been shown to occur in veins including rat skeletal muscle venules (Dornyei et al 
1997), and the dorsal hand vein (Vallance et al 1989). Alterations in NO levels have 
been associated with cardiovascular diseases. Reduction in endothelial NO production 
can lead to abnormal vascular regulation and consequently increased peripheral 
resistance which could lead to hypertension. In hypertensive individuals, the response 
of forearm blood flow to an infusion of L-NMMA is significantly less than that of 
normal individuals: potentially indicating reduced basal NO-mediated vasodilation 
(Calver et al 1992). It is not known whether this occurs due to a reduction in NO 
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release, a decrease of smooth muscle sensitivity to NO, or due to inactivation of NO 
(Vallance and Chan, 2001). 
During early investigations examining endothelial function in blood vessels, it became 
apparent that a vasodilator response remained even after inhibition of prostacyclin and 
NO production. This unidentified mechanism was termed endothelium-derived 
hyperpolarizing factor (EDHF) since it was associated with smooth muscle 
hyperpolarization (Chen et al 1988). 
 
1.9.2. Endothelium-Derived Hyperpolarizing Factor (EDHF) 
EDHF mediated responses are defined as vasodilator modulators which require an 
intact endothelium. They are distinct from endothelium-derived NO and they involve 
hyperpolarizing the vascular smooth muscle and activation of calcium-activated 
potassium channels (KCa). The KCa are activated by calcium released from internal 
calcium stores via phospholipase C and inositol triphosphate-gated Ca2+ release 
channels (Bryan et al 2005). Evidence of the role of K+ channels in the action of EDHF 
comes from the fact that EDHF can be blocked by the intermediate conductance KCa 
channel inhibitors (Vanhoutte, 2004). 
Unlike NO, EDHF has been shown to be more predominant in smaller rather than 
larger arteries, with its impact increasing as vessel size decreases. Shimokawa et al 
(1996) examined the relaxation responses to acetylcholine in rat aorta and proximal 
and distal arteries from the rat mesentery. They observed a greater role for NO in the 
aorta, whereas EDHF had a greater role in the vasodilation of the distal microvessels. 
The hyperpolarization induced by bradykinin was more significant in the distal 
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microvessels than the larger gastroepiploic arteries, which suggests a greater EDHF 
response in the smaller vessels (Urakami-Harasawa et al 1997). Berman et al (2002) 
examined vasodilator responses in different sized arteries from the rabbit ears, and 
found responses to be mediated predominantly by NO in the central ear arteries, while 
EDHF was found to be the predominant vasodilator in the smaller branch arteries. 
Since smaller vessels are often involved in controlling vascular resistance, EDHF may 
play an important role in determining blood flow. 
Parkington et al (2002) provided evidence for a role for EDHF in vivo. In the presence 
of L-NAME and indomethacin, acetylcholine caused a vasodilator response in rat 
mesenteric and hindlimb arteries which was sensitive to the addition of charybdotoxin 
and apamin (EDHF blockers). Furthermore, an important role for EDHF has been 
implicated in humans since L-NMMA reduced basal blood flow of human forearm 
arteries, but did not completely abolish the responses to bradykinin, with the residual 
vasodilator response being attributed to EDHF (Halcox et al 2001). Katz and Krum 
(2001) investigated EDHF responses in healthy human subjects by measuring forearm 
blood flow in response to acetylcholine and comparing the responses with those 
obtained in individuals suffering from chronic heart failure suggesting a more 
prominent role for EDHF during vascular dysfunction. In isolated vessels EDHF 
responses have been observed in rat mesenteric arteries (Cheung et al 1999), bovine 
coronary arteries (Gebremedhin et al 1998) and coronary arteries (He, 2002). As with 
NO, much less information is known about EDHF within the venous system. While 
the evidence above suggests that EDHF has an important role to play in vascular 
control, EDHF has not yet been chemically identified. Several factors have been 
proposed to be EDHF. 
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1.9.3. Epoxyeicosatrienoic Acids  
Epoxyeicosatrienoic acids (EETs) are arachidonic acid–derived products of 
cytochrome P450 epoxygenases. EDHF responses in bovine coronary arteries can be 
blocked by cytochrome P450 inhibitors, SKF 525A and miconazole, TEA (KCa 
channel inhibitor) and high extracellular potassium (Campbell et al 1996). It was 
concluded that EETs activated KCa channels and were responsible for the EDHF 
response. In addition, in bovine coronary arteries, bradykinin caused the release of 
14,15-EET, which in turn caused a concentration-dependent vasodilatation which was 
sensitive to 14,15-EEZE (an EET agonist) (Gauthier et al 2005). However, in human 
mesenteric arteries, blockage of the cytochrome P450 epoxygenase with specific and 
non-specific inhibitors, sulfaphenazole and 17-ODYA, respectively had no effect on 
the EDHF response (Matoba et al 2002). Hence, the involvement of EETs in EDHF 
responses is still controversial. 
 
1.9.4. Potassium ions 
Activation of the endothelial Calcium-sensitive potassium (KCa) channels and 
intermediate conductance calcium activated potassium channels induces efflux of K+ 
ions into the extracellular space (Edwards et al 1998). In rat hepatic arteries, the 
concentration of K+ detected in the myoendothelial space was raised to ~6 mM during 
ACh-induced hyperpolarization (Edwards et al 1998). In these vessels, the increase in 
K+ concentration in the myoendothelial space was abolished in the presence of apamin 
and charybdotoxin, inhibitors of the Calcium-sensitive potassium (KCa) channels, 
intermediate conductance calcium activated potassium channels (IKCa) and large 
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conductance calcium activated potassium channels (Edwards et al 1998). Likewise, in 
human coronary arterioles, flow-induced vasodilatation and hyperpolarization were 
abolished in the presence of charybdotoxin which indicates that KCa channels play a 
role in the shear stress-induced endothelium-dependent vasorelaxation (Miura et al 
2003). 
The efflux of K+ ions from the endothelium can activate the Na+/K+-ATPase pump and 
Kir channels on vascular smooth muscle leading to hyperpolarization and relaxation 
(Edwards et al 1998). In rat hepatic and mesenteric arteries, it was reported that 
extracellular K+ mimics the effect of EDHF response (Edwards et al 1998). These 
EDH-type responses were abolished by the presence of ouabain (Na+/K+-ATPase 
inhibitor) and barium (Kir channel blocker), hence they concluded that K+ is likely to 
be a factor for EDH-type response via activation of the Na+/K+-ATPase and Kir 
channels (Edwards et al 1998).  
However, studies from other laboratories using different vessels; rat hepatic arteries, 
human subcutaneous arteries, porcine coronary arteries, guinea-pig carotid and 
coronary arteries showed that K+ is unlikely to be a factor for EDH-type responses and 
that neither ouabain nor barium had an effect on the bradykinin-induced 
hyperpolarization (Quignard et al 1999). In addition, Lacy et al (2000) demonstrated 
that the response seen to raising extracellular potassium in rat arteries was different 
from the response seen after increasing acetylcholine concentration. Therefore, K+ is 
not the EDHF released by acetylcholine. Furthermore, blocking Na+/ K+ ATPase and 
inward rectifying K+ channels did not block the EDHF response in myogenically active 
mesenteric resistance arteries, thus under physiological conditions K+ is not considered 
as an EDHF (Mathewson and Dunn 2014). 
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1.9.5. Hydrogen peroxide  
Several studies have demonstrated a role for hydrogen peroxide (H2O2) as an EDHF  
(Matoba, et al 2002). Bradykinin-induced EDHF responses in human mesenteric 
arteries were inhibited by addition of catalase (an endogenous peroxidase which breaks 
down H2O2), and by raised extracellular potassium suggesting that H2O2 induced 
hyperpolarization (Matoba, et al 2002). KCa channels have been shown to be involved 
in the H2O2 EDHF-mediated response. Using patch clamp experiments with porcine 
coronary arteries, Barlow and White (1998) demonstrated that H2O2 activates large 
conductance calcium activated potassium channels (BKCa), increasing their open 
probability. H2O2 is a reactive oxygen species, a product of superoxide breakdown by 
either superoxide dismutase or spontaneous breakdown. Superoxides are produced 
from a variety of enzyme including eNOS, cyclooxygenase, lipoxygenase, cytochrome 
P450 epoxygenases and NAD(P)H oxidases. It has been proposed that H2O2 can also 
stimulate large conductance calcium activated potassium channels (BKCa) indirectly 
by increasing arachidonic acid metabolism, and lipoxygenase derivatives of 
arachidonic acid promote vasorelaxation by stimulating large conductance calcium 
activated potassium channels (BKCa) channel activity. 
 
1.9.6. Gap junctions 
Although no universal EDHF has emerged, a large body of evidence has shown a role 
for myoendothelial gap junctions (MEGJ). MEGJ are channels formed between 
endothelial and smooth muscle cells by the docking of two connexons (one from each 
cell). Each connexon is composed of six connexins, which in vascular preparations are 
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predominantly connexins 37, 40 and 43 (Griffith, 2004). Gap junctions allow passage 
of inorganic ions and water soluble molecules smaller than 1kDa. Matoba et al (2002) 
blocked gap junctions with 18α-glycyrrhetinic acid in human mesenteric arteries and 
found that the EDHF response was slightly but significantly reduced. Sandow et al 
(2002) compared EDHF and MEGJ presence in the rat mesenteric and femoral arteries. 
In femoral arteries, acetylcholine did not induce EDHF hyperpolarizations in smooth 
muscle cells, whereas hyperpolarizations were induced in smooth muscle cells in the 
mesenteric arteries. This correlated with the presence of more MEGJ in mesenteric 
arteries than femoral arteries. This may explain why EDHF responses are more 
prominent in small resistance arteries than in conduit arteries. Finally, they stimulated 
the smooth muscle cell and measured hyperpolarizations in the endothelial cells.  
Hyperpolarization was only recorded in the endothelial cells of mesenteric arteries, 
suggesting electrical coupling between the endothelial and smooth muscle cells in 
mesenteric but not in femoral arteries, thus indicating a role for MEGJs. It has been 
proposed that the candidates for EDHF may act by activating MEGJ, with the EDHF 
factors that activate MEGJ varying in different tissues and species (Griffith, 2004). 
 
1.10. Discovery of pannexins 
 
Pannexins are a relatively recently discovered family of proteins that were discovered 
in the year 2000 by Panchin et al They were described as a second family of gap 
junction proteins in the human genome, in addition to the connexins. Four years before 
Panchin discovered the sequence of pannexin1, the protein was cloned and deposited 
in GenBank by Graeme Bolger (1996). He titled the sequence as MRS1. In 2004, 
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Baranova et al worked on the MRS1 clone and recognised the importance of 
pannexin1 as an ATP release channel (Dahl and Keane, 2012).  
Before the discovery of pannexins, there were only two families of gap junction 
proteins namely, connexins and innexins. Connexins are the gap junction proteins 
found in vertebrates (figure 1.5) (Dahl and Keane, 2012). The connexin family of gap 
junction proteins in vertebrates is very well characterised. On the other hand, gap 
junction molecules with no sequence homology to connexins were identified in insects 
and nematodes. These proteins were specific to invertebrates and were termed 
innexins. Panchin was searching for sequences homologous to innexins in the human 
genomes when he discovered the pannexins. The mRNA encoding pannexin 1 
displayed statistically significant similarities to innexins including certain cysteine 
residues and the location of four putative transmembrane domains. Pannexins follow 
a ubiquitous distribution in the animal kingdom and hence the name as suggested by 
Baranova et al (2004) (figure 1.5). 
 
 
Figure 1.5 Gap junction structure and protein membrane topology (Scemes et al 
2007). 
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1.10.1. Structure of pannexins 
The pannexins are a class of integral membrane glycoproteins and are composed of 
three members - pannexin1, pannexin2 and pannexin3 (~ 50-60% sequence similarity 
between them). Both human and mouse genomes contain all three forms of pannexins. 
Pannexin1 and pannexin3 are more homologous to each other, while pannexin2 has a 
larger C terminal domain which conveys unique functions to it, regulation, targeting 
or macromolecular interactions (Figure 1.6) (Yen and Saier, 2007).  
 
  Pannexin 1                                   Pannexin 2                                Pannexin 3  
 
 
Figure 1.6 The structure of pannexins (Penuela and Laird, 2012). 
 
Pannexin proteins span the lipid bilayer of the membrane four times to give rise to two 
extracellular loops and a cytoplasmic loop with the amino and carboxy terminals 
exposed to the cytoplasm. In topology therefore, pannexins are similar to connexins 
and innexins. They differ in the number of cysteine residues in the extracellular loops. 
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There are two cysteine residues in each extracellular loop in pannexins (Scemes et al 
2009). The extracellular loops in pannexins are glycosylated to a high degree and this 
glycosylation is thought to play an important role in preventing pannexins from 
forming gap junctions (Bossa et al 2007). Both the N and C terminals of pannexins are 
least conserved with the C terminal having the highest sequence variability of the two 
(Panchin et al 2000). 
Pannexin membrane channels are formed by six monomers (hexameric oligomers), 
embedded in a single plasma membrane in the case of pannexin1 (Ambros et al 2010; 
Penuela et al 2012) and eight monomers for pannexin2. However, the oligomeric 
number of a pannexin3 membrane channel is not clear yet although it is expected to 
be closer to pannexin1 than pannexin2 due to their similarity in size and sequence 
(Sosinsky et al 2011). The oligomeric form of pannexins is referred to as a pannexon. 
 
1.10.2. The pannexin genes 
The genes for human pannexin1 and pannexin3 are found in the same arm of 
chromosome 11. The gene for pannexin2 is located on chromosome 22. The genes for 
murine pannexin1 and pannexin3 are located in chromosome 9 whereas the pannexin2 
gene is located on chromosome 15 (Baranova et al 2004). It has been reported that 
pannexin1 and pannexin3 share a high degree of sequence homology with each other 
when compared with pannexin2 in both species (Penuela el al 2009). 
Pannexins have a complex gene structure that includes exons and introns. The 
pannexin gene structure with intervening introns throughout their coding sequences 
led to the generation of many different expression products (Penuela et al 2012). In 
addition to the diversity of pannexins being brought about by alternative splicing, post-
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translational modifications also contribute to their diversity. It is thought that 
pannexins do not undergo post-translational phosphorylation, even though they 
contain several phosphorylation sites in their C-terminus, intracellular loop and N-
terminus (Penuela et al 2007 and Barbe et al 2006). Moreover, pannexin1 and 
pannexin3 contain N-glycosylation sites in their extracellular loop and this has been 
confirmed by several mutagenesis studies. Glycosylation of pannexin1 and pannexin3 
occurs at two levels and this leads to the formation of 3 distinct species – the non-
glycosylated species (Gly0), the predominant endoplasmic reticulum resident high 
mannose species (Gly1) and the complex glycosylated species (Gly2). Pannexin2 also 
contains an N-linked glycosylation site in its first extracellular loop and is sensitive to 
deglycosylating enzymes. There are studies that suggest that the N-glycosylation of 
pannexins plays an important role in regulating their distribution since the Gly2 
complex is abundant in the plasma membrane and the Gly0 and Gly1 prefer to reside 
in the endoplasmic reticulum (Penuela et al 2009). 
Pannexin2 seems to undergo an additional post-translational modification - 
palmitoylation. However further studies have to be carried out to confirm this report 
and also to determine if pannexin1 and pannexin3 also undergo palmitolyation 
(Swayne et al 2010). Cysteine residues could play an important role in controlling 
pannexin channels (Bunse et al 2011). It has been observed that when any of the four 
extracellular cysteines of pannexin1 are mutated, the protein loses its channel function 
(Bunse et al 2011 and Wang and Dahl, 2010), hence, it has been suggested that 
cysteines intrinsically control pannexin channel activity by post-translational 
modification processes such as glutathionation or S-nitrosylation. However, more 
studies have to be carried out to confirm if cysteine residues do indeed undergo S-
nitrosylation in pannexin1, as in the case of connexins (Billaud et al 2011). Pannexin1 
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interacts with pannexin2 and pannexin3 in a glycosylation dependent manner. 
Pannexin2 interacts with the Gly0 and Gly1 species of pannexin1 but not with 
pannexin3 (Penuela et al 2009). Studies showed that the C-terminal end of pannexin1 
binds to actin directly. There are further suggestions that the interaction of pannexin1 
and pannexin3 with actin microfilaments as well as cytoskeleton microfilaments is 
mandatory for the proper delivery of pannexin1 and dynamics at the cell plasma 
membrane surface. Moreover, these interactions with the cytoskeleton microfilaments 
help to stabilise the cell surface populations of pannexin1 and pannexin3 (Bhalla-Gehi 
et al 2010). 
 
1.10.3. Pannexin expression and genomics 
The expression of all three pannexins has now been identified in at least seven species 
– humans, mouse, rat, dog, cow, zebrafish and puffer fish (Penuela et al 2013; Yen et 
al 2007). However, they are most well studied in human and murine tissues. It is 
important to note that the expression levels of pannexins are dynamically controlled 
by physiological and pathological processes. For example, pannexin2 is expressed in 
astrocytes only during ischemia or reperfusion (Zappala et al 2007). Also, the 
expression of pannexin1 and pannexin2 increases upon epileptic and seizure activity 
(Zappala et al 2007; Samoilova et al 2003; Zappala et al 2006) 
 
Pannexin1 
Pannexin1 is expressed in several human tissues including the brain, heart, skeletal 
muscle, prostate, lung, liver, small intestine, pancreas, spleen, colon, vascular 
endothelium and erythrocytes (Baranova et al 2004). In the central nervous system, 
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pannexin1 was detected in the cerebellum, cortex, lens, retina, pyramidal cells, 
interneurons, hippocampus, amygdala, substantia nigra, olfactory bulb, neurons 
(Baranova et al 2004; Bruzzone et al 2003; Dvoriantchikova et al 2006, 
Dvoriantchikova et al 2006; Ray et al 2006; Shestopalov et al 2008). The expression 
of pannexin1 was found to be substantial in the brain; however, expression of pannexin 
in lung, kidney, spleen, heart ventricle, skin and cartilage in 3 weeks old mice was 
found to be variable (Penuela et al 2007). Pannexin1 was also found in rodent cochlea 
and in the vascular smooth muscle of TDA (Penuela et al 2007; Wang et al 2009; 
Billaud et al 2011). 
 
Pannexin2  
 The expression of pannexin2 is limited to various area of the human adult brain 
including the cerebellum, cerebral cortex, medulla, occipital pole frontal lobe, 
temporal lobe and putamen (Baranova et al 2004). High levels of pannexin2 were 
detected in rodent brain, spinal cord and eye but on the other hand, rodent thyroid, 
kidney and liver showed low levels of pannexin2 expression (Bruzzone et al 2003; 
Dvoriantchikova et al 2006; Dvoriantchikova et al 2006). There are reports that 
pannexin1 and pannexin2 are co-expressed in several areas of adult rat brain 
(hippocampus), interneuron cells and the Purkinje cells of the cerebellum (Vogt et al 
2005). 
 
Pannexin3  
Pannexin3 has been found in osteoblasts, synovial fibroblasts, skin; mouse paws joint 
and the inner ear cartilage. Additionally, pannexin3 expression was also detected in 
the human hippocampus but at very low levels (Baranova et al 2004).  There are also 
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reports that pannexin3 is expressed in the mouse cochlear bone as well as in the 
prehypertrophic chondrocytes, perichondrium and osteoblasts in embryonic mice 
(Wang et al 2009; Iwamoto, 2010). Pannexin3 is also endogenously expressed in 
osteoblasts, both in murine calvaria and reference cell lines (Bond, 2011 and Penuela, 
2008). 
 
1.10.4. Localisation profiles of pannexins  
Ectopically expressed pannexin1 and pannexin3 predominantly accumulate at the cell 
surface. However, these pannexins are also present within intracellular compartments 
(Penuela et al 2009). Similar distribution profiles have been reported for endogenously 
expressed pannexin1 in a variety of cells and tissues (Bhalla-Gehi et al 2010; Boassa 
et al 2007; Wang et al 2009; Kienitz et al 2011). Though pannexin3 is usually found 
in the intracellular compartments in rat cochlear bone, it has also been found at the cell 
surface and intracellular compartments in murine chondrocytes (Iwamoto et al 2010). 
Pannexin2 localises mainly in intracellular compartments but can also be found in 
limited amounts at the cell surface. The cell surface expression of pannexin2 is 
increased when co-expressed with pannexin1 (Penuela et al 2009). Pannexin1 and 
pannexin3 are found to be especially enriched in dynamic cell surface protrusions at 
areas deficient in contacting cells (Penuela et al 2009).  
 
1.10.5. Pannexin hemichannel modulation 
The pannexin channels are mainly implicated in ATP release and intercellular calcium 
wave propagation. Pannexin1 is also known as a channel for ions, metabolites and 
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signalling molecules with a molecular weight less than 1kDa (D'hondt et al 2011). 
Previous studies report that pannexin1 channels open in response to stimuli like 
mechanical stress or membrane depolarisation and release ATP to the extracellular 
media. It is well documented that various physiological stimuli, including extracellular 
ATP and mechanical stress initiate Ca2+ waves. This calcium wave can be propagated 
by two pathways: either by direct intercellular flux of inositol triphosphate (IP3) 
through gap junction channels or an extracellular pathway involving ATP release and 
purinergic receptors (Hassinger et al 1996).  
The physiological ATP concentration ranges between 1 and 10 mM (Yaginuma et al 
2014). A large gradient between intracellular and extracellular ATP concentration 
drives ATP efflux through the open pannexin1 channel. The amount of ATP released 
has been quantified by bioluminescent luciferin-luciferase based assay which shows 
that the cellular ATP loss is limited. When released into the extracellular spaces, ATP 
and other metabolites like ADP and AMP can bind to purinergic receptors on 
neighbouring cells to produce metabotropic and ionotropic P2X downstream responses 
(Burnstock 2012, Abbracchio et al 2009).  Pannexin hemichannels are also involved 
with entry and exit of other metabolites and fairly large molecules such as 
nicotinamide adenine dinucleotide (NAD+) (Bruzzone et al 2001; Verderio et al 2001), 
prostaglandins (Cherian et al 2005), glutamate, a major excitatory neurotransmitter 
between neurons as well as the neuron-glial signaling network (Bezzi and Volterra 
2001; Ye et al 2003; Stridh et al 2008), glutathione (GSH) (Stridh et al 2008) and 
inositol 1,4,5-trisphosphate (IP3) (Gossman and  Zhao., 2008), which can serve as 
transmitters between cells (Bennett et al 2012). 
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1.11. Functional roles of pannexins 
1.11.1. Paracrine signalling by pannexin1 
a. Calcium waves 
Changes in intracellular calcium ion concentration drives many cellular responses. 
Initiation of calcium ion waves can be brought about by the activation of purinergic 
receptors such as P2Y and P2X in human mesenteric arteries (Matoba et al 2002). 
When ATP binds to P2Y receptors, there is an increase in inositol 1,4,5-triphosphate. 
This in turn, releases calcium ions from the ER. The calcium ions then activate the 
calcium channel and this leads to further release of ATP and proliferation of signals to 
neighbouring cells (Figure 1.7) (Barbe et al 2006; Scemes et al 2009). Pannexin1 is 
known to be a part of the P2X7 receptor complex that is necessary for ATP release 
(Pelegrin and Surprenant, 2006). Similarly, ATP-induced ATP release was also 
observed when pannexin1 channels were activated through P2Y receptors and 
cytoplasmic calcium ions. Thus, pannexin1 plays a role in the initiation and 
propagation of regenerative calcium signalling. In the brain, one hypothesis is that the 
interaction of pannexin1 channels with NMDA receptors releases calcium ions in the 
hippocampal pyramidal neurons, which can promote epilepsy (Thompson et al 2008). 
This role has been confirmed in vivo using mice devoid of pannexin1, as they showed 
that activation of pannexin1 in juvenile mouse hippocampi contributes to neuronal 
hyperactivity in seizures (Santiago et al 2011). 
 
b. Taste sensation 
There are two distinct types of cells that constitute taste buds – the taste receptor 
(receptor cells) and the synapses (presynaptic cells). Pannexin1 is expressed in the 
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receptor cell and on taste stimulation can release ATP (Huang et al 2007). Once ATP 
is released, it can stimulate P2 receptors of the presynaptic cells which in turn release 
serotonin (5-HT). Hence pannexin1 helps in cell to cell signalling and information 
processing within taste buds (Ransford et al 2009). 
 
c. Airway defence 
The primary role of airway epithelial cells is to provide a defence mechanism by 
clearing mucus from the airway. When pannexin1 channels are activated (e.g. under 
hypotonic stress) they can release ATP via pannexin1 channels which then regulates 
ciliary activity which is important for mucus clearance (Ransford et al 2009). 
 
d. Pannexin1 and HIV  
 ATP release through pannexin1 channels is thought to play a significant role in HIV 
viral infection of CD4+ cells.  It has been suggested that the envelope proteins of the 
virus interact with special receptors on CD4+ cells. This interaction triggers ATP 
release though pannexin1 channels and the ATP then interacts with P2Y2 purinergic 
receptors to activate Pyk2 kinases. As a result, membrane depolarisation occurs, 
allowing membrane to membrane fusion and facilitates viral entry into the cell as well 
as cell to cell transmission. Pannexin1 forms a part of the infection synapse that is 
organised by the virus to facilitate infection. In addition to pannexin1, P2Y2 and Pyk2 
are also recruited to the contact site to form a part of this infection synapse (Seror et 
al 2011). This observation is important because by inhibiting any of the components 
mentioned above, HIV infection could be reduced and viral replication could be 
disrupted; hence leading to their use as a potential retroviral therapy (Penuela et al 
2012). 
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1.12. Cellular responses mediated by pannexin1 
a. Immune response 
Pannexin1 interacts with P2X7 receptors to elicit an immune response by releasing the 
cytokine interleukin-1B (IL-1B) in response to the stimulation of the receptors by ATP 
followed by the activation of caspase-1 (Pelegri and Surprenant, 2006). High 
extracellular potassium ion levels in neuronal/astrocytic inﬂammasomes facilitate the 
P2X7 mediated activation of pannexin1 channels (Silverman et al 2009). On the other 
hand, a more recent study stated that pannexin1 channels are not required for the 
assembly of caspase-1-activating inflammasome complex (Qu et al 2011). 
 
b. Tumorigenesis  
The exogenous expression of pannexin1 has been thought to help with tumour 
suppressive properties in C6 gliomas (Lai et al 2007). When pannexin1 is released, the 
C6 gliomas exhibit a flattened morphology and also show a reduction in proliferation, 
motility and anchorage-independent growth. Experiments carried out in nude mice 
determined that cells overexpressing pannexin1 displayed reduced in vivo tumour 
growth when compared to control mice. Thus, they concluded that pannexin1 has an 
important role as a tumour suppressor. A similar study also reported a role for 
pannexin2 (Qu et al 2011; Lai et al 2007).  
 
 
c. Ischemic cell death and epilepsy 
When oxygen and glucose decrease in the mouse hippocampus, it has been suggested 
that pannexin1 channels open and conduct large currents, leading to neuronal death 
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due to significant ionic dysregulation (Thompson et al 2008). Additionally, the 
opening of the pannexin1 channels associated with N-methyl-D-aspartate receptors 
enhances epileptic seizure activity in pyramidal neurons. Studies carried out using 
pannexin1 knockout mice have confirmed that pannexin1 does contribute to severe 
epileptic seizures in vivo (Santiago et al 2011). 
 
d. Apoptosis 
When pannexin1 is co-expressed with P2X7 receptors, ATP induced zeiosis (blebbing) 
in Xenopus oocytes was observed which was not the case was when pannexin1 was 
expressed alone or together with PY2 receptors. Hence, it has been suggested that 
pannexin1 forms a part of the P2X7 death complex (Locovei et al 2006). Pannexin1 
mediates the release of nucleotide signals from apoptotic cells that helps in the 
recruitment of activated monocytes. Therefore, specific cell death signalling happens 
due to the interaction of pannexin1 with P2X7 receptors. Caspases activate pannexin1 
channels and open the channel for ATP and UTP release which help to attract 
phagocytes (Chekeni et al 2010). 
 
e. Keratinocyte differentiation 
It has been observed that when pannexin1 is ectopically expressed, it reduces the 
proliferation rate of rat epidermal keratinocytes. The overexpression of pannexin1 in 
organotypic cultures is known to have a disruptive effect on the overall architecture of 
the epidermis. Pannexin1 reduces the thickness of the living cell layer and also re-
localises cytokeratin 14 (the basal cell marker) throughout the living cell layer. Hence, 
this research argues that pannexin1 has a significant role to play in the regulation of 
keratinocyte differentiation (Celetti et al 2010). 
                                                                     41 
 
1.13. Cellular responses mediated by pannexin2 and pannexin3 
a. Neuronal differentiation  
It has been observed that pannexin 2 is usually expressed by both progenitor neuronal 
cells as well as mature neurons. The expression of pannexin2 in these cells seems to 
be regulated by the presence of the pannexin2 species that has been post-transitionally 
modified by S-palmitoylation. These pannexin2 species are localised in the 
intracellular compartments of the progenitor neuronal cell but not in mature neurons. 
Pannexin2 is re-expressed in the plasma membrane of mature neurons. In addition, 
researchers have observed that when pannexin2 is knocked out in neuro2a cells, it 
significantly enhances the rate of neuronal differentiation (Swayne et al 2010). 
 
b. Differentiation and development  
The channel forming properties of pannexin3 have not been studied in detail. However, 
pannexin3 can reduce the rate of proliferation of epidermis keratinocytes without 
altering their migration properties like pannexin1. Overexpressed pannexin3 however 
maintains the integrity of the epidermis and keratinocyte differentiation in organotypic 
cell lines (Celetti et al 2010). Additionally, it has been reported that pannexin3 
expressed in cartilage, is associated with the differentiation of chondrocytes. 
Pannexin3 specifically promotes ATP release into the extracellular media and thereby 
reduces the proliferation of chondrocytes by decreasing calcium levels and also by 
inhibiting the phosphorylation of CREB in parathyroid hormone-mediated 
chondrocyte proliferation (lwamoto et al 2010). From this study, it can be elucidated 
that pannexin3 has a role in switching the properties of chondrocytes from one of 
proliferation to one of differentiation. Recent reports also suggest that pannexin3 has 
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an important role in chondrocyte and osteoblast differentiation because the pannexin3 
promoter is responsive to Runx2 activation (Bond et al 2011). Pannexin3 can also 
function as an ER calcium channel, plasma membrane channel or even as a gap 
junction protein (Ishikawa et al 2011). Pannexin3 expression has also been associated 
with the simultaneous increase in the expression of connexin Cx43 and therefore it is 
not clear if the gap junction function is due to pannexin3 or due to the increase in Cx34. 
Pannexin3 has also been found to be expressed in rat leydig cells, the apical region of 
the epididymis and in the efferent ducts; hence pannexin 3 could possibly play a role 
in the transport and maturation of sperm (Turmel et al 2011). 
 
1.14. Role of pannexins in vasculature 
Previous studies established the location of pannexin1 on erythrocytes which on 
activation either by stress or hypoxia release ATP. It is also documented that 
pannexin1 channels initiate and propagate Ca2+ waves. Thus, they control blood flow 
by releasing ATP from red blood cells and stimulation of purinergic receptors on 
endothelial cells which causes calcium wave initiation and propagation (Locovei et al 
2006). It has been shown recently by Billaud et al (2011) that pannexin1 has a 
significant role in forming a complex with α1D-adrenergic receptors in vascular 
smooth muscle cells which in turn contributes to vasoconstriction of resistance 
arteries. Thus, pannexin1 could be important in the coordination of vascular smooth 
muscle cell constriction and also the regulation of blood pressure (Penuela et al 2013). 
Billaud et al have shown that after α1-adrenoceptor activation (by phenylephrine) 
pannexin channels open with the subsequent release of ATP. ATP then acts as an 
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intercellular signalling molecule to propagate vasoconstriction by activating P2Y 
receptors on neighbouring cells (Figure 1.7). 
 
 
Figure 1.7 Pannexin1 contributes to α-1-Adrenergic Receptor–Mediated 
Vasoconstriction (Billaud et al 2011). 
 
Burns et al have shown the presence of pannexin1 in vascular smooth muscle and 
pannexin2 in both smooth muscle and the endothelium (Burn et al 2012; Chen, Burns 
et al 2008; Li, He et al 2015). In the smooth muscle of small arteries, pannexin1-
mediated ATP release was shown to participate in vascular tone regulation by 
contributing to arterial contractile response to α1-adrenoceptor activation (Billaud et 
al 2011). By contrast, Dina et al (2014) studied the functional role of pannexin1 in 
facilitating vasodilator and anticontractile effects mediated by the endothelium and 
suggested a major role of pannexin1 in endothelium-dependent responses, mediated 
by EDHF (Figure 1.8). They found that endothelial function was impaired in conduit 
arteries of pannexin1 knockout mice. The mechanism by which pannexins provoke 
their vasorelaxation effects is summarised in Figure 1.8. 
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Figure 1.8 Diagram showing mechanisms of pannexin1 involvement in the 
functioning of EDHF-like mechanism during agonist-induced stimulation followed by 
smooth muscle relaxation. Intermediate conductance calcium activated potassium 
channels (IKCa) – endothelial intermediate conductance calcium-activated potassium 
channels; SKCa – small conductance calcium-activated potassium channels; R – 
receptor; ACh – acetylcholine; Ado – adenosine; ER – endoplasmic reticulum; IP3R 
– 1,4,5-inositol trisphosphate receptor; EC – endothelial cell; IEL – internal elastic 
lamina; SMC – smooth muscle cell; MEGJ – myoendothelial gap junctions; GJ – gap 
junctions; KIR – inwardly rectifying potassium channels. Adapted from Gaynullina et 
al 2015. 
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Aim and objectives  
 
The key aim of this dissertation was to investigate whether pannexin protein was 
present in the porcine splenic and coronary arteries and in the rat thoracic aorta. 
Subsequent functional studies aimed to determine whether pannexins were involved 
in transducing responses to NA and, more importantly, whether they provide a 
mechanism for producing a generalised vasoconstriction in arteries after the discrete 
release of focal neurotransmitters after activation of the sympathetic nerves. Later 
studies investigated whether pannexins are involved in endothelium-dependent 
response in porcine splenic and coronary arteries. 
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Chapter 2 
2. Materials and methods 
2.1. Tissue preparation for Western blotting 
 Porcine tissues 
Tissues were collected from Wood and Sons Abattoir (Clipston, Nottingham, UK) and 
transported to the laboratory in cold Krebs–Henseleit solution. In the dissection room, 
on a clean surface, the porcine splenic and coronary arteries were dissected and placed 
in a petri dish containing sufficient buffer to keep the tissue from drying out where 
they were finely dissected to remove the connective tissue.  
Segments of porcine arteries were extracted and stored at -80 0C. Samples were 
homogenized in lysis buffer [Tris (20mM), ethylene glycol tetraacetic acid (EGTA, 1 
mM), Triton X-100 0.1% (v/v), sodium fluoride (NaF, 1 mM), β-glycerophosphate (10 
mM), pH7.6], containing 1 %(v/v) protease inhibitor cocktail (Sigma-Aldrich,Dorset, 
UK) EDTA free.The samples were then centrifuged at 6000x g for 5 minutes at 4 0C. 
The supernatant was used as total soluble protein sample which was developed using 
PAGE assay. 
 
 Rat aorta 
Male Wistar rats weighting between 180-220g were stunned by a blow to the cranium 
and killed by bleeding. The rat thoracic aorta was dissected and placed in a petri dish 
containing sufficient buffer to keep the tissue from drying out. The rat thoracic aorta 
was finely dissected to remove the connective tissue. 
Segments of rat aorta were extracted and stored at -80 0C. Samples were homogenized 
in lysis buffer [Tris (20mM), ethylene glycol tetraacetic acid (EGTA, 1 mM), Triton 
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X-100 0.1% (v/v), sodium fluoride (NaF, 1 mM), β-glycerophosphate (10 mM), 
pH7.6], containing 1 %(v/v) protease inhibitor cocktail (Sigma-Aldrich,Dorset, UK) 
EDTA free.The samples were then centrifuged at 6000x g for 5 minutes at 4 0C. The 
supernatant was used as total soluble protein sample which was developed using 
PAGE assay. 
 
2.2. Lowry test  
A Lowry test was used to determine the protein concentration of the supernatants 
(Lowry et al., 1951). A stock bovine serum albumin (BSA, 1mg/ml) solution was 
prepared in distilled water; a serial dilution (from 0.05-0.45 mg/ml) was prepared from 
the stock to produce a standard curve. Supernatants and standards were mixed with 
Lowry A (0.4 % (w/v) NaOH, 0.2 % (w/v) sodium dodecyl sulphate (SDS), 2 % (w/v) 
Na2CO3) and Lowry B (1 % (w/v) CuSO4, 2 % (w/v) NaK Tartrate), and incubated 
for 10 minutes at room temperature. Subsequently, folin phenol reagent, diluted 1:1 in 
distilled water, was added to the supernatants and standards and incubated for 45 
minutes at room temperature. The samples were then transferred to a 96 well plate and 
the absorbance was measured using SpectraMAX 340 PC plate reader at 750 nm 
wavelength. The protein concentrations of the samples were extrapolated from the 
BSA standard curve. 
The supernatant from the remaining samples (not used in the Lowry test) was diluted 
1:6 in solubilisation buffer (6x SB, 24 % (w/v) SDS, 30 % (v/v) glycerol, 5 % (v/v) 
beta mercaptoethanol, 2.5 % (v/v) bromophenol blue, 1.5M Tris-hydrochloride, pH 
6.8) and heated at 95 oC for 5 minutes, followed by centrifugation for 1 minute at 
13000x g. 
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2.3. Western blotting 
Samples were run on on 4-20 % Tri Glycine (PAGE) Gold Precast Gels (Bio Rad, 
Hercules, CA, USA) in electrophoresis buffer (0.19 M Tris hydrochloride, 1.9 M 
glycine and 35 mM SDS). The lysis samples were placed in the heat block for 5 
minutes at 95°C. Following this they were vortexed and centrifuged for 1 minute at 
6000x g. 
One μl of the molecular marker (Bio-Rad, precision plus protein) was loaded in the 
first well and the rest of the wells were loaded with 5µg of the porcine tissue and 10µg 
of the rat aorta sample. Electrophloresis was performed at 175V for 35 minutes using 
Bio-rad mini protean 3 electrophloresis tank. The gel was blotted onto nitrocellulose 
membranes which was performed at 100V for 60 minutes at 4°C. To check for transfer 
of protein, ponceau s solution (Sigma, UK) was added to the nitrocellulose membrane, 
which was then washed in tris buffered saline solution with the detergent Tween® 20 
(TBST) (25mM Tris, 12mM NaCL, 10l dH2O, 10ml Tween 20, pH 7.6). Following 
this, the nitrocellulose membrane was blocked in 5% (w/v) milk solution in TBST for 
1 hour at room temperature on a rocking platform. After that the nitrocellulose 
membrane was incubated overnight at 4oC with the primary antibodies Rabbit anti-
pannexin1 (Abcam cat No. ab124969), Rabbit anti- pannexin2 (Abcam cat No. 
ab55917) and Rabbit anti-pannexin3 (Abcam cat No. ab98093, added at 1:1000 
concentration in 5% (w/v) milk solution Mouse monoclonal anti-GAPDH antibody 
(G8795 Sigma, UK) (1:40 000) was simutaniously used as house keeping and loading 
control. All antibodies where sealed in a plastic bag with the nitrocelluose and 
incubated over night at 4oC. 
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The following day the primary antibodies were removed by putting the nitrocellulose 
membrane in a glass container and washing with TBST (3 rinses, 3x5 minute washes 
and 3x15 minute washes). In the final step the nitrocellulose membranes were 
incubated again for 1 hour at room temperature with with to the corresponding 
secondary antibodies: IRDye® 680LT Goat anti-mouse IgG (1:10 000) (LI-COR 
Biosciences, Cambridge, UK) and IRDye® 800CW Goat anti-rabbit IgG (1:10 000) 
(LI-COR Biosciences, Cambridge, UK).After that the secondary antibodies were 
removed and the nitrocellulose was washed as before (3rinses, 3x5 minute washes and 
3x15 minute) and analysed using Li-Cor Odyssey Imager Scanner and densities of the 
bands were determined using Odyssey (Application Software Version 3.0LI-COR 
Biosciences, Cambridge, UK). 
 
2.4. Immunohistochemistry 
2.4.1. Paraffin embedding tissue and sectioning 
Porcine splenic and coronary arteries and rat thoracic aorta were dissected and placed 
in a sponged petri dish full of Krebs–Henseleit solution, where they were finely 
dissected to remove the connective tissue, then cut to 1 cm in length, immediately 
placed in 4% formaldehyde and incubated overnight at 4º C. The next day, tissues were 
processed using a Leica bio-system tissue processor 1020 for the tissue to dehydrate. 
A gentle exchange was achieved by passing the tissue through increasing 
concentrations of ethyl alcohol (50, 70, 90, 96 & 100%). Once the water had been 
replaced by alcohol, the alcohol was then replaced with xylene, which is a transitional 
solvent which is miscible with both the alcohol and molten wax. The final step in 
processing was to infiltrate the tissue with molten paraffin wax. The following day, 
                                                                     50 
 
the tissue is arranged in a steel mould in the correct orientation for example the porcine 
arteries were arranged transversely and embedded in molten wax. They were then left 
to cool and harden prior to sectioning. 5µm sections were cut using a Leica RM2125 
microtome (Leica), floated in a water bath set to 42˚ C and transferred to 3-
Aminopropyltriethoxysilane (APES) coated slides, which is a chemical solution used 
to add a charge to the slides, thus helping sections to adhere to the slides better. The 
slides were then left to dry. 
 
2.4.2. Histology 
APES coated slides containing 5µm sections were dewaxed using xylene over 5 
minutes.  The sections were then rehydrated by immersing the slides in Industrial 
Methylated Spirits (IMS), moving through 2x100%, 90% 70%, 50% then down to 
water each step was done for for 30 seconds.  
For the antigen retrieval, slides were placed onto a plastic rack and positioned in a 
microwavable plastic container containing citrate saline buffer (10mM Sodium 
Citrate, 0.05% Tween 20, pH 6.0). The container was then moved into the microwave 
with the lid on. The slides were then irradiated at mid-high power for 5 minutes 
followed by 15 minutes in low power then left under running cold tap water for 15 
minutes. They were then permeabilized using 0.1% triton in phosphate-buffered saline 
(PBS) for 10 minutes, blocked with 10% goat serum for 30 minutes to prevent non –
specific staining and then drained off. The primary antibodies were diluted in (PBS 
0.1%, 0.1% Tween-20, 1% bovine serum albumin (BSA)) to a dilution of 1:500. This 
dilution was chosen following optimisation and successful use in immunostaining 
experiments using same antibody concentration in different tissue. The slides were 
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then placed in a humidity chamber and the primary antibodies were applied to the 
sections and left to bind overnight (24 h). No primary antibody was applied to the 
negative control; instead blocking solution only was applied overnight. The excess 
primary antibody was removed the following day by washing with PBS. Then the 
secondary antibody, The goat anti-rabbit  antibody (secondary antibody) FITC (F0382) 
was diluted to 1:500 and goat anti-rabbit IgG (H+L) secondary antibody, Rhodamine 
Red conjugate was diluted to 1:1000 in (PBS 0.1%, 0.1% Tween-20, 1%BSA) and 
applied to the sections for 1 h. The excess secondary antibody was then removed by 
washing with PBS. The slides were placed in a humidity chamber which was then 
covered in aluminium foil to prevent bleaching of the Rhodamine red and FITC 
marker. After1 hour, excess antibody was removed by washing with PBS. Following 
this they were incubated with DAPI (1in 500 dilution) for 5 min in the dark. Incubation 
with DAPI was followed by 2 washes with TBS. Coverslips were placed on 
microscope slides applied using mounting medium (1% (v/v) 1, 4-diazobicyclo-[2, 2, 
2,]-octane (DABCO) fluorescence mounting medium-SS04. Slides were then stored 
and covered with aluminium foil. 
 
2.4.3. Fluorescence microscopy 
The immunostaining sections were viewed using a light microscope and a wide field 
fluorescence microscope (Leica DMRB). Sections were viewed at 20x and 40X (plan, 
air objective with a 0.5 NA) magnifications to assess pannexin location in the arteries. 
Images were captured using Micro Manager. The following filters were used to 
visualise the immunostains. DAPI - Excitation 350/50nm, emission 460/50 nm, FITC 
- Excitation 480/40nm, emission 535/50 nm to visualise the Goat anti-rabbit Antibody 
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and Rhodamine Red - Excitation 545/20nm, emission 610/75 nm for the Goat anti-
rabbit IgG (H+L) secondary antibody. 
 
2.5. Isometric tension recording 
Porcine tissue was obtained from Wood and Sons Abattoir (Clipston, Nottingham, 
UK) from breeds of modern hybrid pig, but the sex and exact age of each animal was 
unknown. Porcine spleens and hearts were isolated at the abattoir and stored in Krebs–
Henseleit solution at 4˚C during transport to the laboratory. On arrival, gross dissection 
of splenic arteries and coronary arteries were carried out leaving the adipose and 
connective tissue directly surrounding the vessels intact. Vessels were stored overnight 
in Krebs–Henseleit solution at 4˚C pre-gassed with a 95% O2: 5% CO2 gas mixture. 
The next day vessels were pinned in a dissection dish and the remaining adipose and 
connective tissue was removed whilst ensuring vessels were not stretched or damaged. 
The length of the vessel segments was approximately 5 mm. Tissue was kept in Krebs–
Henseleit solution and allowed to normalize to room temperature before being setup 
in the isometric force transducer   . 
 
Vessels were attached to two metal hooks placed through the lumen, ensuring that the 
hooks were not overlapping. One hook was attached to a glass rod and the other was 
attached to a non-stretchable silk thread. The vessel was then transferred to an organ 
bath where the glass rod was anchored into the system (Figure 2.1). The thread 
attached to one of the hooks was attached to a force transducer (AD Instruments, UK) 
on a rack and pinion, enabling adjustment of tension. The organ bath contained 20ml 
Krebs–Henseleit solution and was kept at a constant temperature of 37 ˚C using a 
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thermal circulator pump. The Krebs–Henseleit solution was constantly gassed with the 
required gas mixture for each experiment. 
 
The force transducer was attached to a Bridge Amplifier (ADInstruments, UK) to 
measure alterations in voltage recorded by the transducer due to changes in the tension 
applied to the transducer. The Bridge Amplifier was in turn connected to a PowerLab 
unit (AD Instruments, UK), which connected the transducer to a computer where data 
was recorded using Lab Chart software (AD Instruments, UK). Transducers were 
calibrated with a 10g weight daily to ensure consistency of measurement. 
 
 
Figure 2.1 Pictorial representation of the apparatus used in the isometric tension 
recording experiments 
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2.6. Statistics analysis 
Data analysis was carried out using Prism (Graph Pad Software). 
Data was expressed as mean ± standard error of the mean (s.e.m). Where the N 
represents the number of animals used in every experiemnt. The difference between 
means was considered statistically significant at a value of P < 0.05. Statistical 
significance was determined using two-tailed unpaired Students t-test between two 
data sets or one-way ANOVA when comparing multiple data-sets. One-way ANOVA 
was followed by a Bonferroni post hoc test carried out as appropriate (Prism 6.0 
software (San Diego, CA)).  
Contractions to all agonists were measured in grams and expressed as a percentage of 
the KCl-induced contraction in porcine tissue and expressed as grams in rat tissue. In 
Electrical field stimulation experiment the responses were measured in grams and 
expressed as a percentage of NA-induced contractions. The contractions to 5HT and 
U46619 were expressed as a percentage of their own maximum response in porcine 
tissue and as grams in rat tissue. All data are presented as mean +/- standard error of 
the mean (s.e.m). In some experiments, the log concentration-response curves were 
used to determine potency (log EC50 values) and maximum response (Rmax) values. 
EC50 is the concentration of a drug that produces a response equal to 50% of the 
maximum response (GraphPad Prism software). 
To assess the affinity of antagonists at α1-adrenoceptors in the porcine splenic artery, 
log EC50 values were obtained in the absence and presence of different concentrations 
of the antagonist and further used for Schild analysis, using the following equations: 
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DR = 
EC50`
EC50
 
 
KB =
(DR − 1)
A
 
Where (DR) is concentration ratio, (EC50`) is the concentration of the agonist that 
causes 50% of the observed action in presence of the antagonist, (EC50) is the 
concentration of the agonist that causes 50% of the observed action in absence of the 
antagonist and (A) is the concentration of the antagonist. Subsequently a Schild plot 
(Arunlakshana et al 1959) was performed by plotting log (DR-1) against the logarithm 
of the concentration of the antagonist. From the equation, the slope of the plot was 
obtained and the intersection of the log (DR-1) with the x-axis was used to determine 
the -logKB (pA2) value of the antagonist. 
In the endothelium dependent vasorelaxation study the data are presented as mean 
percentage relaxation of U46619-induced tone with standard error of the mean 
(s.e.m.). The maximum percentage relaxation (Rmax) and the negative log of 
concentration required to produce half the maximal relaxation of the induced tone 
(EC50) were calculated by fitting the data to the logistic equation: 
R=
Rmax X AnH
EC50nH+AnH
 
Where R is the reduction in tone, Rmax is the maximum vasorelaxation of the 
established tone; A is the concentration of the vasorelaxant. nH is the slope function 
and EC50 is the concentration of the vasorelaxant required to produce half the maximal 
relaxation (McCulloch & Randall, 1998). Data were analysed using one-way ANOVA 
was used for multiple groups, P-values of less than 0.05 were considered statistically 
significant. 
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2.7. Drugs and solutions 
The following solutions used were: 
Krebs–Henseleit solution contains (in mM/L): NaCl 118; KCl 4.8; NaHCO3 25; 
KH2PO4 1.25; MgSO4.7H2O 1.2; Glucose 11.1; and CaCl2 1.25. 
  
Calcium-free Krebs–Henseleit solution 
The composition of the calcium-free Krebs–Henseleit solution, in mM, was as follows: 
(118 mM NaCl, 4.8mM KCl, 1.1 mM MgSO4, 25 mM NaHCO3, 1.2 mM KH2PO4, 
and 11.6 mM D-glucose) 
 
The following compounds were used 
Ethylene diamine tetra-acetic acid disodium salt (EDTA) (BDH Laboratory Supplies, 
England), noradrenaline, carbenoxolone, 2-(2,6-
Dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane hydrochloride (WB 4101) 
hydrochloride, 5HT 5-Hydroxytryptamine hydrochloride , pannexin 1 blockers – 
mefloquine and probenecid, Brilliant Blue FCF,  Pyridoxalphosphate-6-azophenyl-
2',4'- disulfonic acid (PPADS), thromboxane A2 mimetic, 9,11-dideoxy-11 alpha, 9 
alpha-epoxy-methano-prostaglandin F2 alpha (U46619), 4,4',4'',4'''-
[Carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonylimino))]tetrakis-1,3 
benzenedisulfonic acid, octasodium salt (NF449), N-nitro-L-arginine methyl ester 
hydrochloride (L-NAME), indomethacin, bradykinin and Guanethidine (Sigma, UK) 
and prazosin hydrochloride (Sigma, UK). 
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The drugs used in this study was made up in distilled water except for NA which was 
made up in 23µM EDTA, and probenecid, U46619 and mefloquine and indomethacin 
which were dissolved in ethanol with further dilutions made up from the original stock.    
 
Antibodies 
Anti- pannexin1, Anti- pannexin2 and Anti-pannexin3 antibodies used for western 
blotting were purchased from Abcam (UK) and LI-COR Biosciences. All antibodies 
were made up to a final concentration of 1:1 000 using semi-skimmed milk. 
 The goat anti-rabbit IR Dye antibody (secondary antibody) was purchased from LI-
COR (UK) and was made to a final concentration of 1:1 000 using skimmed milk. An 
anti- pannexin1 (AV42783-50UG) antibody used for immunohistochemistry was 
purchased from Sigma, UK and was made up to a final concentration of 1:500 using 
semi- skimmed milk. The goat anti-rabbit IRDyeantibody (secondary antibody) FITC 
(F0382) was purchased also from Sigma, UK and was made up to a final 
concentrateion of 1:1000 in (PBS 0.1%, 0.1% Tween-20, 1%BSA). Goat anti-rabbit 
IgG (H+L) Secondary antibody Rodamine Red conjugate (R-6394) was purchased 
from (Thermo Scientific) and was made up to a final concentration of 1:1000 (PBS 
0.1%, 0.1% Tween-20, 1%BSA). 
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Chapter 3 
3. Pannexin function in porcine splenic artery 
3.1. Introduction  
Pannexin channels were first discovered by Panchin (2000) as integral membrane 
proteins in mammalian genomes. The pannexin family comprises three members, i.e. 
pannexin-1, pannexin-2, and pannexin-3 (Bond and Naus, 2014). These proteins have 
some resemblance in their membrane topology to connexons (Ambrosi et al 2010; Kar 
et al 2012). However, the role for pannexin-1 oligomers (that forms a channel between 
the cytosol and extracellular space) is different from that of connexon oligomers (that 
form intercellular gap junctions between adjacent cells). The key dissimilarity is 
possibly due to the mechanism whereby pannexin-1 is exceedingly glycosylated on its 
extracellular loops, which might inhibit docking with pannexin-1 channels on the 
adjacent cells (Ohbuchi et al 2011; Poornima et al 2012; Sorge et al 2012; Sumi et al 
2010). Pannexin-1 is present in many human tissues (Cea et al 2014; Abeele et al 2006; 
Baranova et al 2004; Shestopalov and Panchin, 2008), whereas the expression of 
pannexin-2 is more limited to the central nervous system (Ray et al 2006; 
Dvoriantchikova et al 2006), and pannexin-3 is expressed in many cultured cell lines 
(Ishikawa et al 2011; Bond et al 2011; Turmel et al 2011). Recently pannexins have 
been shown to be expressed in the vasculature (Billaud et al 2011), and while their 
function has yet to be fully determined, Billaud et al (2011) proposed a mechanism by 
which the vasoconstriction induced by α1-adrenoceptors in thoracodorsal resistance 
arteries involved pannexin1 channels. They found that phenylephrine acting upon the 
α1D-adrenoceptors caused release of ATP through pannexin channels in mouse 
thoracodorsal small arteries. ATP then activated P2 receptors on neighbouring smooth 
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muscle cells to enhance vasoconstriction. They concluded that pannexin1 could 
contribute to the coordination of vascular smooth muscle cell constriction and the 
regulation of blood pressure as an intermediary for catecholamines released by 
sympathetic nerves (Billaud et al 2011). Although Billaud et al (2011) have presented 
evidence for the involvement of pannexins in controlling the constriction of 
thoracodorsal resistance arteries. The role of pannexins in mediating responses to NA 
in other arteries has not been studied. Hence, the aim of this chapter was to build on 
the research carried out by Billaud et al (2011) to provide an overall understanding of 
the role of pannexin in the regulation of vascular tone. The objectives were to 
determine (i) the presence of pannexins in PSA by (using Western blot and 
immunohistochemistry), (ii) the α1-subtype population responsible for mediating NA-
induced vasoconstriction in PSA, and (iii) whether pannexins are involved in 
mediating contractile responses produced by exogenous NA or activation of the 
sympathetic nerves in PSA.  
 
3.2. Material and methods 
3.2.1. Westren blotting 
Porcine spleens were collected from the abattoir and processed as described in section 
2.3. Samples were run on 7% SDS-PAGE gels using a Biorad Mini-protein 3 system 
as described in section 2.3 Subsequently, the nitrocellulose membrane was incubated 
overnight with the primary antibody Rabbit anti-pannexin1 (Abcam cat No. 
ab124969), Rabbit anti-pannexin2 (Abcam cat No. ab55917) and Rabbit anti-
pannexin3 (Abcam cat No. ab98093 which were added at 1:1 000 concentration in 
5%(w/v) milk solution, and mouse monoclonal anti-GAPDH antibody (G8795 Sigma, 
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UK) (1:40 000), followed by incubation with corresponding secondary antibodies 
IRDye®680LT Goat anti-mouse IgG (1:10 000) (LI-COR Biosciences, Cambridge, 
UK) and IRDye® 800CW Goat anti-rabbit IgG (1:10 000) (LI-COR Biosciences, 
Cambridge, UK) for 1 hour at room temperature. After that the secondary antibodies 
were removed and the blots where washed the images where processed on a Licor 
Odyessy scanner using Image studio v3.0 software. 
 
3.2.2. Immunohistochemistry 
3.2.2.1. Paraffin embedding tissue and sectioning 
Porcine splenic arteries were dissected from the spleen and processed as described in 
section 2.4.1. Immunohistochemistry experiment was performed as described in 
section 2.4.1. The primary antibodies were diluted in (PBS 0.1%, 0.1% Tween-20, 
1%BSA) and incubated overnight, while the secondary antibody, goat anti-rabbit 
FITC, was diluted in (PBS 0.1%, 0.1% Tween-20, 1%BSA) to a dilution of 1:500. And 
applied to the sections for 1 h. Following this they were incubated with DAPI (1in 500 
dilution) for 5 min in the dark. Coverslips were placed on microscope slides using 
mounting medium (1% (v/v) 1, 4-diazobicyclo-[2, 2, 2,]-octane (DABCO) DABCO 
fluorescence mounting medium-SS04. The slides and sections were examined at X20 
and X40 using a light microscope and a wide field Fluorescence microscope to assess 
pannexin location. The following filters were used to visualise the immunostains. 
DAPI - Excitation 350/50nm, emission 460/50 nm, FITC - Excitation 480/40nm, 
emission 535/50 nm to visualise the Goat anti-rabbit Antibody. 
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3.2.3. Isometric tension recording 
3.2.3.1. Tissue collection and sample preparation 
Porcine splenic arteries were dissected cut into 4 equal strips approximately 5mm in 
length as described in section 2.5.k Four sets of experiments were carried out to 
investigate the contractile response of porcine splenic arteries to NA in the absence 
and presence of pannexin inhibitors (mefloquine or probenecid or carbenoxolone) or 
P2 receptor antagonist (PPADS or suramin). 
 
3.2.3.2. The general protocol for recording isometric tension 
As described in section 2.5, segments were exposed to increasing concentrations of 
NA (10-8 -10-4M) raised in 3–fold increments to generate cumulative concentration 
curves (CCRC) to NA. The concentration of NA was changed by adding appropriate 
amounts of NA to the bath as soon as the previous concentration had produced a 
plateau. After the CCRC was completed, tissues were washed and the whole procedure 
was repeated again to check the reproducibility of the CCRC curves after a further 30-
minute equilibration period. This was compared to CCRC curves to NA generated in 
the presence of either suramin (10-4M), PPADS (10-5M), mefloquine (2x10-5M) or 
probenecid (5x10-4M). 
Experiments were also carried out on porcine splenic artery using 5HT and U46619 as 
contractile agents. 5HT was applied at concentrations between 3x10-10 and 10-8M and 
U46619 at concentrations from 3x10-8 to 10-6M to produce cumulative concentration 
curves. The effect of mefloquine (2x10-5) M on 5HT and U46619 responses were then 
determined. 
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3.2.3.3. Electrical field stimulation experiment in porcine splenic artery 
Porcine splenic artery ring segments were set up as described previously. Tissues were 
exposed to NA (10-5 M), followed by a washout using Krebs’-Henseleit solution. 
Exposure to NA was repeated at least twice before tissues were exposed to electrical 
field stimulation (EFS). EFS was applied to the artery segments at increasing 
frequencies (1, 2, 5, 10, 20Hz, at a voltage of 20 V, pulse width 0.5ms, for 10s) at 5 
minutes intervals using an SRI electrical stimulator. Frequency- response curves were 
repeated in the presence and absence of mefloquine (2x10-7, 2x10-6, 2x10-5), 
probenecid (5x10-4M) carbenoxolone (10-5, 2x10-5 and10 -4 M), suramin (10-4M), and 
PPADS (10-5M). 
 
3.2.4. Statistical analysis 
As described in section 2.6. 
 
3.3. Results 
3.3.1. Western Blotting analysis 
Western blot analysis was carried out to determine pannexin1 and pannexin2 
expression in PSA using anti-pannexin1 and 2 specific antibodies. 
 
1. Pannexin1 expression in porcine splenic artery  
The expression of pannexin1 was shown as a 50 kDa band in all samples. The lanes 
show splenic artery samples from 11 different pigs. The 50 kDa bands observed during 
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western blotting correspond to pannexin1 protein (http://www.abcam.com/pannexin-
1-antibody-EPR5556-ab124969-references.html) (Figure 3.1). 
 
 
 
 
 
Figure 3.1 Western blot analysis to determine pannexin1 expression in porcine splenic 
artery. N =11. 
 
2. Pannexin2 and pannexin3 expression in porcine splenic artery 
The expression of pannexin2 was shown as a 100kDa band in all lanes. The lanes show 
splenic artery samples from 4 different pigs. The 100kDa bands observed during 
western blotting correspond to the pannexin2 protein 
(http://www.abcam.com/pannexin-2-antibody-ab55917-references.html). In addition, 
the expression of pannexin3 (http://www.abcam.com/pannexin-3-antibody-
ab98093.html). Was examined using anti-pannexin3 antibody, but the expression of 
pannexin3 was not evident in PSA as we did not detect a band corresponding to 
pannexin3 (Figure 3.2). 
 
Figure 3.2. Western blot analysis to determine pannexin1 and pannexin2 expression 
in porcine splenic artery. N = 4.
Anti-pannexin1 
Anti-GAPDH 37kDa 
25kDa 
75kDa 
50kDa 
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3.3.2. Pannexin1 expression assessed by immunohistochemistry in porcine 
splenic artery 
Immunolabelling of pannexin1 using anti-pannexin1 specific antibody was carried out 
in cross sections and showed endothelium and smooth muscle cells of porcine splenic 
artery labelled for presence of pannexin1 under light and fluorescence microscope at 
20X and 40X. The image shows expression of pannexin1 in the endothelium and the 
smooth muscle cells of porcine splenic artery (Figure 3.3). 
 
Figure 3.3. Light microscopic images of porcine splenic artery at X20 (a) stained 
without primary antibody. Expression of pannexin1 shown by immunohistochemistry 
in the absence (b) and presence (c) of anti-pannexin1 specific antibody at X20. 
Expression of pannexin1 shown by immunohistochemistry in the absence (d) and 
presence (e) of anti-pannexin1 specific antibody at X40. Expression was evident in the 
endothelium and the smooth muscle cells of porcine splenic artery. N =6. 
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3.3.3. Isometric tension recording 
3.3.3.1. Eeffect of noradrenaline on tension of porcine splenic artery 
To test whether the response to NA was reproducible in PSA, consecutive 
concentration-response curves were obtained. The maximum responses did not 
significantly alter between the two curves; Rmax values were 230.3 ± 27.58% and 221.4 
± 37.8% of the KCl response for curves one and two, respectively (Figure 3.4). 
Similarly, the sensitivity to NA did not change between the curves; Log EC50 values 
were -6.04 ± 0.27 and -6.33 ± 0.28 for curves one and two, respectively (p >0.05, 
Student’s t-test, N = 8). 
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Figure 3.4 Responses to noradrenaline in the porcine splenic artery. The contractions 
caused by noradrenaline were expressed as a percentage of the contraction produced by 
KCl. Data are presented as the mean value ± s.e.m. There was no significant difference 
between the concentration-response curves (P>0.05, Student’s t-test, N = 8). 
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3.3.3.2. Effect of mefloquine on noradrenaline induced contraction in 
porcine splenic artery 
Mefloquine at 2x10-5M reduced the magnitude of NA-induced contraction in PSA. The 
maximum responses to NA were 231.2 ± 8.87% in the absence and 118.3 ± 9.44% in 
the presence of mefloquine (P < 0.0001, Student’s t-test, N=7) (Figure 3.5). However, 
mefloquine did not alter the sensitivity of responses to NA in PSA; log EC50 values were 
-5.69 ± 0.08 in the absence and -5.62 ± 0.16 in the presence of mefloquine (P > 0.05, 
Student’s t-test) (Figure 3.5). 
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Figure 3.5 Effect of mefloquine (2 x10-5M) on the response to noradrenaline in the 
porcine splenic artery. The contractions caused by noradrenaline were expressed as a 
percentage of the contractions produced by KCl. Data are presented as the mean value 
± s.e.m. Differences between Rmax values are shown by **** P < 0.0001 (Student’s 
paired t-test, N=7). 
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3.3.3.3. Effect of probenecid on noradrenaline induced contraction in 
porcine splenic artery 
Probenecid (2x10-3M) significantly reduced the response to NA in the PSA. The 
responses to NA (3x10-4M) were reduced from 158.83 ± 11.14% in the absence to 96.64 
± 14.14% in the presence of probenecid (2x10-3M) (p < 0.001, Student’s t-test, N =8) 
(Figure 3.6). However, probenecid did not alter the sensitivity of responses to NA in 
PSA (p > 0.05, Student’s t-test) (Figure 3.6). 
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Figure 3.6 Effect of probenecid (2x10-3M) on the response to noradrenaline in the 
porcine splenic artery. The contractions caused by noradrenaline were expressed as a 
percentage of the contractions produced by KCl. Data are presented as the mean value 
± s.e.m. Differences between Rmax values are shown by *** P < 0.001 (Student’s paired 
t-test, N = 8). 
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3.3.3.4. Effect of carbenoxolone on noradrenaline-induced contraction in 
porcine splenic artery 
Carbenoxolone, used at three different concentrations of 10-5, 2x10-5 and 10 -4M did not 
alter the magnitude of NA-induced contraction in PSA. The maximum responses to NA 
were 149.9 ± 11.31% (control) and 145.8 ± 7.84% in the presence of carbenoxolone (10-
5M) (p > 0.05, Student’s paired t-test, N = 5), the sensitivity (Log EC50) was -6.25 ± 
0.13 (control) and -6.75 ± 0.13 (carbenoxolone (10-5M)) (p >0.05, Student’s paired t-
test) (Figure 3.7a). The maximum responses to NA were 170.9 ± 34.65% (control) and 
143.7 ± 17.17% in the presence of carbenoxolone (2x10-5M) (p >0.05, Student’s paired 
t-test, N = 5), the sensitivity was -5.84 ± 0.27 (control) and -5.65 ± 0.14 (carbenoxolone 
(2x10-5M)) (p > 0.05, Student’s paired t-test) (Figure 3.7b). The maximum responses to 
NA was 175.7 ± 24.86% (control) and 156.5 ± 16.07% in the presence of carbenoxolone 
(10-4M) (p > 0.05, Student’s paired t-test, N = 5), the sensitivity was -6.07 ± 0.21 
(control) and -5.80 ± 0.13 (carbenoxolone (10-4M) (P>0.05, Student’s paired t-test) 
(Figure 3.7c). 
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Figure 3.7 Effect of carbenoxolone (10-5, 2x10-5 and10-4M) on the response to 
noradrenaline in the porcine splenic artery. The contractions produced by noradrenaline 
were expressed as a percentage of the contractions caused by KCl. Data are presented 
as the mean value ± s.e.m. Carbenoxolone did not alter the contraction to noradrenaline 
in porcine splenic artery (P>0.05, Student’s t-test, N = 5). 
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3.3.3.5. Effect of suramin and PPADS on noradrenaline-induced 
contraction in porcine splenic aretry 
Suramin (10-4M) did not reduce the magnitude of NA-induced contraction in PSA. The 
maximum responses to NA were 186.2 ± 76.80% in the absence and 132.9 ± 19.18% in 
the presence of suramin (P >0.05, Student’s t-test, N =8) (Figure 3.8a). Suramin did not 
alter the sensitivity of responses to NA in PSA; log EC50 values were -5.99 ± 0.54 in the 
absence and in -6.41 ± 0.19 the presence of suramin (P >0.05, Student’s t-test). 
Likewise, PPADS (10-5M) did not alter the magnitude of NA-induced contraction in 
PSA. The maximum responses to NA were 175.0 ± 8.48% in the absence and 188.7 ± 
14.21% in the presence of PPADS (10-5M) (P >0.05, Student’s t-test, N =8) (Figure 
3.8b). Also, PPADS did not alter the sensitivity to NA; log EC50values were -5.92 ± 
0.10 in the absence and -5.79 ± 0.15 in the presence of PPADS (P >0.05, Student’s t-
test). 
                                                                     71 
 
-9 -8 -7 -6 -5 -4
0
1 0 0
2 0 0
C o n tro l
S u ra m in , 1 0
-4
M
L o g  [N A ] M
%
 o
f 
K
C
l 
c
o
n
tr
a
c
t
io
n
-9 -8 -7 -6 -5 -4
0
100
200
Control
PPADS, 10-5M
Log [NA] M
%
 o
f 
K
C
l 
c
o
n
tr
a
c
ti
o
n
a
b
 
Figure 3.8 Effect of suramin (10-4M) (a) and PPADS (10 -5M) (b) on the response to 
noradrenaline in the porcine splenic artery. The contractions caused by noradrenaline 
were expressed as a percentage of the contractions caused by KCl. Data are presented 
as the mean value ± s.e.m. Suramin (a) and PPADS (b) did not change the contraction 
to noradrenaline in the porcine splenic artery (P>0.05, Student’s t-test, N =8). 
 
3.3.3.6. Reproducibility of responses to EFS in porcine splenic artery 
To examine whether the vasoconstriction response to EFS was reproducible in PSA, 
consecutive responses to EFS were obtained. EFS-induced contraction of PSA was 
reproducible as there were no significant differences between the responses (P > 0.05, 
Two-way ANOVA, N = 6) (Figure 3.9).  
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Figure 3.9 (a) Representative trace showing the vasoconstrictor responses to nerve 
stimulation in porcine splenic artery. (b) EFS responses to 5 different frequencies (1, 
2, 5, 10, 20Hz, 90 V, 5ms, 10s), the contraction was expressed as a percentage of the 
response produced by noradrenaline (10 -5M). Each Colum represents the mean ± 
s.e.m. There was no significant difference between the responses (P > 0.05, Two-way 
ANOVA, N = 6). 
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3.3.3.7. Role of α1-adrenoceptors and/or P2X receptors in mediating 
electrically-evoked vasocontractile responses in porcine splenic artery 
Under basal tone conditions, EFS elicited frequency-dependent vasoconstrictor 
responses in the PSA (20V, pulse width 0.5msec) at frequencies 1, 2, 5, 10 and 20 Hz 
applied for 10s. Guanethidine, a sympatholytic compound (5x10-6M), abolished 
vasoconstriction response evoked by EFS in the PSA at 10Hz and 20Hz (p<0.05, p 
<0.0001, Two-way ANOVA) (Figure 3.10). 
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Figure 3.10 Electrical field stimulation responses to 5 different frequencies (1, 2, 5, 10, 
20Hz, 90 V, 5ms, 10s) were expressed as a percentage of the response produced by 
noradrenaline (10-5M). Each Column represents the mean ± s.e.m. Contractile responses 
were abolished in the presence of guanethidine (5x10-6) (*P < 0.05, ****P < 0.0001, 
Two-way ANOVA, N = 4). 
 
3.3.3.8. Effect of mefloquine on responses to EFS in the porcine splenic 
aretry 
Mefloquine at 2x10-6 and 2x10-7M did not alter the contraction-induced by EFS (p > 
0.05, Two-way ANOVA) (Figure 3.11a, b). Mefloquine at 2x10-5 M significantly 
reduced the vasoconstriction response evoked by EFS in the porcine splenic artery at 
20Hz (p < 0.0001, Two-way ANOVA, N = 8) (Figure 3.11c). 
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Figure 3.11. Effect of mefloquine (2x10 -7, 2x10 -6, 2x10-5M) on the response to EFS in 
the porcine splenic artery. Responses to nerve stimulation were expressed as a 
percentage of the response produced by noradrenaline (10-5M). Each column represents 
the mean ± s.e.m. Mefloquine at 2x10-7 (a) and 2x10-6M (b) did not alter the contraction-
induced by EFS (P > 0.05, Two-way ANOVA, N = 8). Mefloquine at 2x10-5M (c) 
significantly reduced responses to EFS in porcine splenic artery at the highest frequency 
applied (20Hz) (***P < 0.0001, Two-way ANOVA, N = 8). 
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3.3.3.9. Effect of probenecid on responses to EFS in the porcine splenic 
artery 
Probenecid (2x10-3M) significantly reduced the contraction response evoked by EFS in 
the PSA at 10Hz and 20Hz (P < 0.001, Two-way ANOVA, N = 8) (Figure 3.12). 
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Figure 3.12. Effect of probenecid (2x10-3M) on the response to EFS in the porcine 
splenic artery. Responses to nerve stimulation were expressed as a percentage of the 
response produced by noradrenaline (10-5). Each column represents the mean ± s.e.m. 
Probenecid decreased the contraction to EFS at 10Hz and 20 Hz (***P < 0.001, Two-
way ANOVA, N = 8). 
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3.3.3.10. Effect of carbenoxolone on responses to EFS in the porcine splenic 
artery 
Carbenoxolone (10-4M) did not alter the contraction to EFS in PSA (Figure 3.13).  
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Figure 3.13. Effect of carbenoxolone (10-4M) on the response to EFS in the porcine 
splenic artery. Responses to nerve stimulation were expressed as a percentage of the 
response produced by noradrenaline (10-5). Each column represents the mean ± s.e.m. 
Carbenoxolone had no significant effect on the contraction to EFS (P > 0.05, Two-way 
ANOVA, N = 4). 
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3.3.3.11. Effect of suramin on responses to EFS in porcine splenic artery 
Suramin (3x10-4M) did not alter the contraction to EFS in PSA (Figure 3.14).  
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Figure 3.14. Effect of suramin (3x10-4M) on the response to EFS in the porcine splenic 
artery. Responses to nerve stimulation were expressed as a percentage of the response 
produced by noradrenaline (10-5M). Each column represents the mean ± s.e.m. Suramin 
had no significant effect on the contraction to ESF (P > 0.05, Two-way ANOVA, N = 
5). 
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3.3.3.12. Effect of PPADS on responses to EFS in the porcine splenic artery 
PPADS (10-5M) did not alter the contraction to EFS in PSA (Figure 3.15).  
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Figure 3.15. Effect of PPADS (10-5M) on the response to EFS in the porcine splenic 
artery. Responses to nerve stimulation were expressed as a percentage of the response 
produced by noradrenaline (10-5). Each column represents the mean ± s.e.m. PPADS 
had no significant effect on the contraction to ESF (P>0.05, Two-way ANOVA, N = 8). 
 
3.3.3.13. Effect of mefloquine to 5-HT and U46619 in the porcine splenic 
artery 
In order to investigate the specificity of mefloquine, responses to 5-HT and U46619 
were obtained in the absence and presence of mefloquine (2x10-5M). Mefloquine 
significantly reduced the maximum response to 5-HT in the PSA. The maximum 
responses to 5-HT were reduced from 125.78 ± 28.1% in control to 18.86 ± 8.47% in 
the presence of mefloquine (p < 0.001, Student’s paired t-test; N = 4) (Figure 3.16a). In 
addition, mefloquine (2x10-5M) reduced the response to U46619 in the PSA. The 
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maximum responses to U46619 were reduced from 117.7 ± 9.057% in control to 125.7 
± 6.2% in the presence of mefloquine (P < 0.001, Student t-test, N=4) (Figure 3.16b). 
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Figure 3.16 Effect of mefloquine (2x10-5M) on the responses to 5-HT (a) and U46619 
(b) in the rat aorta. The contractions caused by 5-HT and U46619 are represented as a 
percentage of the contractions caused by KCl (60mM).  Data are presented as the mean 
value ± s.e.m. Differences between Rmax values are shown by ***P < 0.001, (Student’s 
paired t-test, N = 4). 
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3.3.3.14. The effect of α1A-adrenoceptor antagonist on responses to 
phenylephrine in the porcine splenic artery 
PSA was exposed to cumulative concentrations of phenylephrine (10-8 to 3x10-4M) in 
the absence and presence of three concentrations of WB 4101 (10-7, 3x10-7 and 10-6M), 
then a Schild plot (N = 6) was constructed. WB 4101 caused a concentration-dependent 
rightward displacement of the phenylephrine concentration-response curve. The data 
from six observations was drawn for which the slope was 1.21 ± 0.17, pA2 value was 
9.67 (Figure 3.17). 
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Figure 1.17 (a) The response to cumulative concentrations of phenylephrine (10-8 to 
3x10-4M) were determined in the absence and presence of WB 4101 (10-7, 3x10-7 and 
10-6 M). The contractions caused by phenylephrine were expressed as a percentage of 
KCl-induced contraction. Data are presented as the mean value ± s.e.m (N = 6). (b) 
Schild plot was presented by plotteing the logarithm of dose ratio-1 (DR-1) against the 
logarithm of the concentration of the antagonist. (N = 6). 
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3.3.3.15. Effect of α1D-adrenoceptor antagonist, BMY 7378, on responses to 
phenylephrine in the porcine splenic artery 
PSA was exposed to cumulative concentrations of phenylephrine (10-8 to 3x10-4M) in 
the absence and presence of three concentrations of BMY 7378 (10-9, 3x10-9 and 10-8 
M), then a Schild plot (N = 6) was constructed. The data from six observations was 
drawn for which the slope was 1.08 ± 0.26 and the pA2 value was 7.35 (Figure 3.18). 
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Figure 3.18 (a) The response to cumulative concentrations of phenylephrine (3×10-8 to 
10-4M) were determined in the absence and presence of BMY 7378 (10-8, 3x10-8 and 10-
7 M). The contractions caused by phenylephrine were expressed as a percentage of KCl-
induced contraction. Data are presented as the mean value ± s.e.m (N = 6). (b) Schild 
plot was presented by plotting the logarithm of dose ratio-1 (DR-1) against the logarithm 
of the concentration of the antagonist. (N = 6). 
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3.4. Discussion 
The aim of this chapter was to determine whether pannexins were present in the porcine 
splenic artery (PSA) and to examine their possible function. The results from the 
Western blot studies showed that pannexin1 and pannexin2 are both present in PSA. 
Inhibitors of pannexin channels (i.e. mefloquine and probenecid) significantly reduced 
the responses of PSA to (i) NA-induced contractions and (ii) the frequency-dependent 
response curves generated to nerve stimulation. In contrast, carbenoxolone, one of the 
first agents shown to directly inhibit pannexin1 currents (Bruzzone et al 2005), had no 
effect on responses to either exogenous NA or nerve stimulation in the PSA. 
Furthermore, neither suramin nor PPADS (P2 receptor antagonists) had any effect on 
responses to either exogenous NA or nerve stimulation. Thus, the present data do not 
support the hypothesis proposed by Billaud et al (2011), who suggested alpha-
adrenoceptor stimulation involved the release of ATP through pannexin channels, to 
invoke a multicellular contraction by activating P2 purinoceptors. The actions of 
mefloquine may be non-selective since it also reduced responses to 5-HT and U46619. 
3.4.1. Expression of pannexin in porcine splenic artery 
Western blot analysis was carried out using anti-pannexin1 and anti-pannexin 2 
antibodies. Both pannexin1 and pannexin2 expression was shown in PSA tissues. Both 
pannexin1 and pannexin2 were detected in PSA at 50kDa and 100kDa respectively, 
however pannexin3 was not detected. The primary antibody used was rabbit anti- 
pannexin antibody while goat anti-rabbit was used as a secondary antibody. Burns et al 
(2012) have shown the presence of pannexin1, pannexin2 and pannexin3 in rat middle 
cerebral artery.  
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3.4.2. Localization of pannexin1 
Immunolabelling of pannexin1 in PSA shows pannexin1 expression in both endothelial 
and smooth muscle cells. Pannexin1 has been observed in both the endothelium and 
smooth muscle of smaller arteries and arterioles. It is restricted to the endothelium in rat 
aorta and femoral artery (Billaud et al 2011; Lohman et al 2012), and the smooth muscle 
cells of the rat middle cerebral artery (Burns et al 2012). Pannexin2 has been found in 
endothelial and smooth muscle cells of the rat middle cerebral artery (Burns et al 2012), 
and pannexin3 has been reported in small arteries less than 100 μm in diameter, 
particularly in the kidney (Lohman et al 2012). Pannexin1 expression has also been 
reported in human erythrocytes (Locovei et al 2006), although a more recent experiment 
to detect the protein in these cells with different antibodies was unsuccessful (Melhorn 
et al 2013) 
Billaud et al (2011) suggested that pannexin1 contributes to α1-adrenoreceptor-mediated 
vasoconstriction in thoracodorsal resistance arteries isolated from mice. Both pannexin1 
inhibitors (i.e. mefloquine and probenecid) and purinergic receptor antagonists (i.e. 
suramin and reactive blue-2) were shown to reduce phenylephrine -induced 
vasoconstriction. Therefore, it has been speculated that phenylephrine binds to the α1D-
adrenoreceptor, causing pannexin1 to open to release ATP, which then acts as an 
intercellular messenger to cause P2 receptor-mediated contractions.  
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3.4.3. Effect of pannexin inhibition on responses to noradrenaline and EFS 
in the porcine splenic artery 
Although the mechanism by which mefloquine and probenecid bind to pannexin 
channels remain speculative, one theory proposed is that probenecid (a blocker of 
organic anion transporters) may either access pannexin channels through the lipid 
bilayer or interact either with hydrophilic aspects of the protein (Silverman et al 2008). 
Probenecid is known to inhibit pannexin1 channels with an IC50 of ~150 μM, whereas 
it does not have an effect on connexin-based channels regardless of its concentration 
(Silverman et al 2008).  
In the present study, at concentrations reportedly selective for pannexin channels, both 
probenecid and mefloquine reduced NA-induced contractions and those caused by 
activating the sympathetic nerves in the PSA. These data could be taken as evidence 
that pannexin channels are involved in conducting responses to NA in this blood vessel.  
This is similar to the observations in TDA from mice where 10 μM and 20 μM of 
mefloquine and 500μM of probenecid produced a considerable inhibitory effect on the 
response of TDA of mice to phenylephrine (a selective α1-adrenoreceptor agonist). 
However, there are justifiable grounds to question whether these compounds are acting 
selectively. Angus et al (2015) recently showed mefloquine (10–20 μM) to demonstrate 
a wide range of inhibitory actions. For example, mefloquine (3–10 μM) inhibited the 
contractions mediated by vasopressin, phenylephrine, endothelin-1, U46619, 
sympathetic nerve stimulation and K+ (40 mM) in rat and mouse small mesenteric 
arteries. In the present study, the present study also showed that mefloquine inhibited 
responses to both 5-HT and the thromboxane mimetic, U46619. It is possible that 
pannexins are involved in transducing responses to any G-protein coupled receptor. 
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However, data presented in chapter 4 shows that inhibition of the influx of calcium is a 
more likely consequence, such that mefloquine produces a non-selective inhibition of 
contractile responses. Mefloquine (10 μm) has been shown to inhibit L-type Ca++ 
currents in single ventricular myocytes (Coker et al 2000).  
Further evidence against a role for ATP released from inside cells via pannexin channels 
in the PSA is provided by the lack of effect of carbenoxolone. This compound has been 
shown to interact with pannexins. For example, Sridharan et al (2010) showed 
carbenoxolone (100 μM) to inhibit the hypotonically induced ATP release from human 
erythrocytes. Even at this concentration, carbenoxolone had no effect on NA responses, 
either exogenous, or after nerve activation. Similarly, Angus et al (2015) showed that 
carbenoxolone had no effect on agonist or nerve-induced activation of alpha-
adrenceptors in rat small mesenteric resistance arteries.  
Furthermore, while suramin (100 µM to 300 µM) has been shown to inhibit P2 
receptors, leading to decreased contractility of TDA induced by phenylephrine (Bilaud 
et al 2011). Neither suramin nor PPADS had any effect on responses to exogenous NA 
in the PSA, ruling out a role for ATP-activation of P2 receptors in transducing an α1-
adrenoceptor-mediated response in the PSA. Interestingly, neither P2 receptor 
antagonist affected responses to nerve stimulation indicating that ATP is not a functional 
sympathetic neurotransmitter in this preparation, in contrast to some other blood vessels 
including rat mesenteric arteries (Rummery et al 2007; Pakdeechote et al 2007) and 
porcine mesenteric arteries (Shatarat et al 2014), although in the latter preparation, some 
pharmacological manipulation was required before a nerve-mediated purinergic 
response was observed.  
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3.4.4. α 1-adrenoceptor subclassification  
Billaud et al (2011) reported that the pannexin channels formed a signalling domain 
with α1D-adrenoceptors, therefore, to determine the subtype of α1-adrenoceptor present 
in the PSA experiments were conducted with subtype selective α1-adrenoceptor 
antagonists. The pA2 values obtained for WB-4101 and BMY-7378 were 9.67 and 7.35 
respectively. The slopes for either antagonist did not vary from unity showing that both 
antagonists competitively antagonise phenylephrine-induced contractile responses in 
the PSA (Barbieri et al 1998; Muramastsu et al 1990). These pA2 values are in 
agreement with the values available in the literature for WB-4101 (9.46) and BMY-
7378 (6.91) antagonists acting at α1A-adrenoceptors and α1D-adrenoceptors respectively 
(Barbieri et al 1998), and identify α-adrenoceptors in the PSA as being predominantly 
α1A-adrenoceptors. In another study, WB-4101 antagonised α1A–adrenoceptors in rat 
caudal arteries with a pA2 value of 9.14 (Villalobos-Molina and Ibarra, 1996). 
The aim of the next chapter therefore, was to examine whether pannexins were involved 
in mediating responses to NA in a preparation that contained α1D-adrenoceptors, namely 
the rat thoracic aorta. 
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Chapter 4 
4. Pannexin function in rat aorta  
4.1. Introduction 
The sympathetic nervous system plays a significant role in controlling blood pressure 
by acting at two types of adrenoceptors, i.e. α–and β–adrenoceptors (Nash, 1990). The 
α–adrenoceptors have been divided into two subtypes: α1–adrenoceptors (located mostly 
on postjunctional vascular smooth muscle cells) and α2–adrenoceptors (located on 
prejunctional sympathetic nerve endings and postjunctionally in some blood vessels) 
(Nash, 1990). The α1-adrenoceptors are G protein-coupled receptors that signal 
thorough Gαq/11, leading to the activation of phospholipase Cβ with the subsequent 
production of inositol phosphates and diacylglycerol, leading to the release of calcium 
from the calcium stores and the activation of protein kinase C (O'Connell et al 2013). 
The α1–adrenoceptors are currently classified into three subtypes: α1A–adrenoceptors, 
α1B–adrenoceptors and α1D–adrenoceptors (Civantos Calzada and Aleixandre de 
Artinano 2001). The α1A–adrenoceptor subtype has been implicated in the maintenance 
of vascular basal tone and of arterial blood pressure, whereas the α1B–adrenoceptor 
subtype has been suggested to have a role in responding to exogenous agonists. α1D–
adrenoceptors are also found in the vasculature and this is the principal subtype present 
in rat mesenteric and carotid arteries and in the rat aorta (Villalobos-Molina & Ibarra, 
1996). A recent study has shown that α1D–adrenoceptors can form a complex with 
pannexin proteins, such that after activation, intracellular ATP is released to act as an 
intercellular signalling molecule, to consolidate adrenergic-mediated vascular 
contraction (Billaud et al 2011). In the previous chapter, purinoceptor antagonists had 
no effect on responses mediated by α1A–adrenoceptors in porcine splenic arteries, 
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questioning a role for ATP, released via pannexin channels, subsequent to activating 
this receptor. Therefore, in this chapter, responses to noradrenaline were examined in 
the rat thoracic aorta, where the major α1–adrenoreceptor subtype has been reported to 
be the α1D–adrenoceptor (Kenney et al 1995). The first objective was, therefore, to 
determine the presence of pannexin protein in rate aorta by using Western blot and 
immunohistochemistry. Additionally, the role of pannexin channels and ATP (via P2 
purinoceptors) in contributing to the vascular tone in RA in response to exogenous NA 
was assessed using pannexin blockers (mefloquine, probenecid, and BB-FCF), P2 
receptor antagonists (suramin, PPADS and NF449) and apyrase (an enzyme that breaks 
down ATP).  
 
4.2. Methods and Materials 
4.2.1. Western blotting  
Male Wistar rats weighing between 180-220g were sacrificed and the aorta was 
dissected as described in section 2.3. Samples were run on 7% SDS-PAGE gels using a 
Biorad Mini-protein 3 system as described in section 2.3. Subsequently, the 
nitrocellulose membrane was incubated overnight at 4oC with the primary antibody  
Rabbit anti-pannexin1 (Abcam cat No. ab124969, Rabbit anti-pannexin2 Abcam cat No. 
ab55917 and Rabbit anti-pannexin 3 Abcam cat No. ab98093 at 1:1 000 concentration 
in 5% (w/v) milk solution and mouse monoclonal anti-GAPDH antibody (G8795 
Sigma-Aldrich) (1:40 000  followed by incubation with secondary antibodies : 
IRDye®680LT Goat anti-mouse IgG (1:10 000) (LI-COR Biosciences, Cambridge, 
UK) and IRDye®800CW Goat anti-rabbit IgG (1:10 000) (LI-COR 
Biosciences,Cambridge, UK) for 1 hour at room temperature. After that the 
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nitrocellulose membrane was analysed using Li-Cor Odyssey Imager Scanner and 
densities of the bands were determined using Odyssey (Application Software Version 
3.0LI-COR Biosciences, Cambridge, UK). 
 
4.2.2. Isometric tension recording 
4.2.2.1. Rat aorta 
The rat aorta was dissected and cut into 4 equal segments approximately 5mm in length 
as described in section 2.1. Experiments were carried out to investigate the contractile 
response of rat aorta to NA in the presence and absence of pannexin inhibitors 
(mefloquine, probenecid and Brilliant Blue FCF) and in the absence and presence of P2 
purinoceptor antagonists (PPADS, suramin and NF449) or the ectonucleotidase 
(apyrase). 
 
4.2.3. Immunohistochemistry 
4.2.3.1. Paraffin embedding tissue and sectioning 
Rat aorta were dissected and processed as described in section 2.4.1. 
Immunohistochemistry experiment was performed as described in section 2.4.1. The 
primary antibodies were diluted to 1:500 in (PBS 0.1%, 0.1% Tween-20,1%BSA) and 
incubated overnight, while the secondary antibody, rodamine red conjugate, was diluted 
t in (PBS 0.1%, 0.1% Tween-20, 1%BSA) to a dilution of  1:1000 and applied to the 
sections for 1 h. Following this they were incubated with DAPI (1in 500 dilution) for 5 
min in the dark. Coverslips were applied using mounting medium (1% (v/v) 1, 4-
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diazobicyclo-[2, 2, 2,]-octane (DABCO) fluorescence mounting medium-SS04. The 
slides were examined at 20 and 40 magnifications using a microscope to assess pannexin 
location. Sections were viewed, 20X magnification. The following filters were used to 
visualise the immunostains. DAPI - Excitation 350/50nm, emission 460/50 nm, 
Rhodamine Red - Excitation 545/20nm, emission 610/75 nm for the Goat anti-rabbit 
IgG (H+L) secondary antibody. 
 
The general protocol for recording isometric tension 
Rat thoracic artery segments were set up in organ baths for isometric tension recording 
as described in section 2.5. Segments were then exposed to increasing concentrations of 
NA (10-8-10 -4M) raised in 3–fold increments to generate cumulative concentration 
curves (CCRC) to NA. After the CCRC was completed, it was compared to CCRC 
curves to NA generated in the presence of either, mefloquine (2x10-5M), probenecid 
(5x10-4M), suramin (10-4M), PPADS (10-5M), Brilliant Blue FCF (10-6,10-5M), NF449 
(10-7,10-6,10-5M), or ectonucleotidase (apyrase) 1U/ML. Experiments were also carried 
out using 5-HT and U46619 as contractile agents. The effect of mefloquine (2x10-5M) 
on 5-HT and U46619 responses were determined. In addition, experiments were carried 
out to determine whether either pannexin inhibitors or purinoceptor antagonists affected 
responses to KCl. To do this, tension was raised using KCl (60 mM) and the 
inhibitors/antagonists were added to the organ bath in increasing concentrations at 30 
min intervals. Some tissues were not exposed to drugs and acted as controls. 
To assess whether mefloquine affected Ca2+ entry mechanisms, arteries were set up as 
described above. Vessels were incubated in Ca2+-free Krebs–Henseleit solution and left 
for 30 mins. Thereafter, the extracellular Ca2+ concentration was increased between 
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(1µM and 3 mM) in three-fold increments, to generate a cumulative concentration-
response curve. This was also carried out in tissues exposed to mefloquine (2x10-7, 
 2x10-6 or 2x10-5M). 
 
4.2.4. Statistical analysis 
As described in section 2.6. 
 
4.3. Results 
4.3.1. Pannexin1, 2 and 3 expression in rat thoracic aorta tissue  
Western blot analysis on RA tissue using anti-pannexin1 antibodies showed a 50 kDa 
band in all samples. The 50 kDa bands observed during western blotting correspond to 
pannexin1 protein (http://www.abcam.com/pannexin-1-antibody-EPR5556-ab124969-
references.html) (Figure 4.1).  
 
 
Figure 4.1 Western blot analysis to determine pannexin1 expression in rat aorta tissue. 
N = 6. 
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Western blot analysis on Rat aorta tissue using anti-pannexin2 antibodies showed 
100kDa bands in all lanes. The 100kDa bands observed during western blotting 
correspond to the pannexin2 protein (http://www.abcam.com/pannexin-2-antibody-
ab55917-references.html) (Figure 4.2). In addition, the expression of pannexin3 protin 
(http://www.abcam.com/pannexin-3-antibody-ab98093.html) was examined using anti-
pannexin3 antibody, but the expression of pannexin3 was not evident in Rat aorta as I 
did not detect a band corresponding to pannexin3 (data not shown). 
 
 
Figure 4.2 Western blot analysis to determine pannexin2 expression in Rat aorta tissue. 
N = 4. 
 
4.3.2. Pannexin1 expression assessed by immunohistochemistry in rat 
aorta 
The immunostaining sections were viewed using a light microscope and a wide field 
fluorescence microscope (Leica DMRB). Sections were viewed at 20X and 40X 
magnifications to assess pannexin location in the arteries. Images were captured using 
Micro Manager. The following filters were used to visualise the immunostains. DAPI - 
Excitation 350/50nm, emission 460/50 nm, FITC - Excitation 480/40nm, emission 
535/50 nm to visualise the Goat anti-rabbit Antibody and Rhodamine Red - Excitation 
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545/20nm, emission 610/75 nm for the Goat anti-rabbit IgG (H+L) secondary antibody 
(Figure 4.3). 
 
 
Figure 4.3. Light microscopic images of rat aorta at X20 (a) stained without primary 
antibody. Expression of pannexin1 shown by immunohistochemistry in the absence (b) 
and presence (c) of anti-pannexin1 specific antibody at X20. Expression of pannexin1 
shown by immunohistochemistry in the absence (d) and presence (e) of anti-pannexin1 
specific antibody at X40. Expression was evident in the endothelium and the smooth 
muscle cells of porcine splenic artery. N =6. 
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4.3.3. Isometric tension recording 
4.3.3.1. Effect of noradrenaline on tension of rat aorta 
To test whether the response to NA was reproducible in RA, consecutive concentration-
response curves were obtained. NA induced a concentration-dependent contraction in 
the RA (Figure 4.4). The maximum responses did not significantly differ between the 
two curves; Rmax values were 0.72± 0.06g and 0.72± 0.08g for curve one and two, 
respectively (Figure 4.4). In addition, the sensitivity to NA did not change between the 
curves; log EC50 values were -7.8±2.5 and -7.3 ± 2.8 for curve one and two, respectively 
(p > 0.05, Student’s Paired t-test, N = 6).  
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Figure 4.4 Responses to noradrenaline in rat thoracic aorta. Curve 1 is shown as closed 
circles, while curve 2 is shown as open circles. Data are presented as the mean value ± 
s.e.m. There was no significant difference between the concentration-response curves 
(P > 0.05, Student t-test, N = 6). 
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4.3.3.2. Effect of mefloquine on noradrenaline-induced-contraction in Rat 
aorta 
Mefloquine, used at three different concentrations; 2x10-7M, 2x10-6M and 2x10-5M, 
reduced the magnitude of NA-induced contraction in Rat aorta. The maximum 
responses to NA were reduced from 1.06 ± 0.11g in control to 0.82 ± 0.01g in the 
presence of mefloquine, 2x10-7M (p < 0.01, Student’s paired t-test; N = 5), but this 
concentration of mefloquine did not alter the sensitivity to NA in Rat aorta; log EC50 
values were -7.08 ± 0.30 (control) and -6.68 ± 0.26 (mefloquine, 2x10-7M) (Student’s 
paired t-test; N = 5) (Figure 4.5a). The maximum responses to NA were reduced from 
1.31 ± 0.14g in control to 0.63 ± 0.13g in the presence of mefloquine, 2x10-6M (p < 
0.0001, Student’s paired t-test; N = 5), but this concentration of mefloquine did not alter 
the sensitivity to NA in RA; log EC50 values were -6.74 ± 0.22 (control) and -7.14 ± 
0.69 (mefloquine, 2x10-6M) (Student’s paired t-test; N = 5) (Figure 4.5b). The maximum 
responses to NA were reduced from 1.16 ± 0.1g in control to 0.44 ± 0.03g in the presence 
of mefloquine, 2x10-5M (p < 0.001, Student’s paired t-test; N = 5), and the log EC50 
value was reduced from -6.94 ± 0.23 (control) to -6.44±0.27 (mefloquine, 2x10-5M) (p 
< 0.01, Student’s paired t-test; N = 7) (Figure 4.5c). 
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Figure 4.5 Effect of mefloquine at 2x10-7(a), 2x10-6 (b) and 2x10-5M (c) on the response 
to noradrenaline in the rat aorta. Controls are shown as closed circles, while drug 
treatment is shown as open circles. Each point represents the mean ± s.e.m. Differences 
between Rmax values are shown by **P < 0.01; ***P < 0.001, ****P<0.0001 (Student’s 
paired t-test, N = 5-7). 
                                                                     98 
 
4.3.3.3. Effect of probenecid on noradrenaline-induced contraction in rat 
aorta 
Probenecid, used at three different concentrations of 2x10-5, 2x10-4 and 2x10-3M, 
reduced the magnitude of NA-induced contraction in RA. The maximum responses to 
NA were reduced from 0.98 ± 0.12g in control to 0.70 ± 0.04g in the presence of 
probenecid (2x10-5M) (p < 0.01, Student’s paired t-test; N = 5), and the sensitivity (Log 
EC50) was reduced from -7.41 ± 0.32 (control) to -6.75 ± 0.13 (probenecid, 2x10
-5M) (p 
< 0.05, Student’s paired t-test; N = 5) (Figure 4.6a). The maximum responses to NA 
were reduced from 1.41 ± 0.14g in control to 0.65 ± 0.052g in the presence of probenecid 
(2x10-4M) (p < 0.001, Student’s paired t-test; N = 5), and the sensitivity was reduced 
from -7.41 ± 0.28 (control) to -6.69 ± 0.17 (probenecid, 2x10-4M) (p < 0.05, Student’s 
paired t-test; N = 5) (Figure 4.6b). The maximum responses to NA were reduced from 
0.9 8± 0.11g in control to 0.43 ± 0.05g in the presence of probenecid (2x10-3M) (p < 
0.0001, Student’s paired t-test; N = 5), and the sensitivity was reduced from -7.41 ± 0.32 
(control) to -6.49 ± 0.21 (probenecid, 2x10-3M) (p < 0.05, Student’s paired t-test; N = 
5) (Figure 4.6c). 
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Figure 4.6 Effect of probenecid at 2x10-5 (a), 2x10-4 (b) and 2x10-3M (c) on the response 
to NA in the rat aorta. Controls are shown as closed circles, while drug treatment is 
shown as open circles. Each point represents the mean ± s.e.m. Differences between 
Rmax values are shown by **P < 0.01; ***P < 0.001, ****P < 0.0001 (Student’s paired 
t-test, N = 5). 
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4.3.3.4. Effect of BB-FCF on noradrenaline-induced contraction in rat 
aorta 
Brilliant Blue FCF (BB-FCF) is structurally similar to the purinergic receptor antagonist 
Brilliant Blue G (BBG), which is an inhibitor of ionotropic P2X7 receptors. It has also 
shown to be a selective inhibitor of pannexin1 channels (Wang et al 2013). BB-FCF 
at10-6 and 10-5M had no effect on the magnitude or sensitivity of NA-induced 
contraction in RA (Table 4.1) (Figure 4.7a, b).  
Table 4.1 Effects of BB-FCF on NA-induced contraction in Rat aorta  
Treatment Rmax(g) Log EC50(M) 
Control 0.80 ± 0.06 -7.19 ± 0.19 
BB-FCF 10-6M 0.75 ± 0.04 -7.17 ± 0.12 
Control 0.87 ± 0.05 -7.25 ± 0.15 
BB-FCF 10-5M 0.88 ± 0.05 -7.25 ± 0.14 
Data represent the mean ± s.e.m of 4 experiments 
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Figure 4.7 Effect of BB-FCF (a) 10-6 and (b) 10-5 M on the response to noradrenaline 
in rat aorta. Controls are shown as closed circles, while drug treatment is shown as open 
circles. Each point represents the mean ± s.e.m. BB-FCF had no significant effect on 
the contraction induced by NA. (P > 0.05, Student t-test, N=4). 
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4.3.3.5. Effect of suramin and PPADS on noradrenaline-induced 
contraction in rat aorta 
Suramin (3x10-4M) and PPADS (10-5M) had no effect on the magnitude of NA-induced 
contraction in RA (Table 4.2) (Figure 4.8a, b). Furthermore, neither suramin nor PPADS 
altered the sensitivity of responses to NA in RA (Table 4.2) (Figure 4.8a, b). 
 
Table 4.2 Effects of Suramin and PPADS on NA-induced contraction in RA 
Treatment      Rmax(g)     Log EC50(M) 
Control 0.08 ± 0.07 -7.55 ± 0.30 
        Suramin3x10-4M 0.71 ± 0.07 -7.78 ± 0.30 
Control 0.78 ± 0.07 -7.55 ± 0.23 
        PPADS 10-5M 0.67 ± 0.07 -7.93 ± 0.35 
Data represent the mean ± s.e.m of 4 experiments 
 
                                                                     103 
 
-1 0 -8 -6 -4
0 .0
0 .5
1 .0 C o n tro l
S u ra m in , 3  x  1 0
-4
M
L o g  [N A ] M
C
o
n
tr
a
c
ti
o
n
 (
g
)
-10 -8 -6 -4
0.0
0.5
1.0
Control
PPADS, 10-5M
Log [NA] M
C
o
n
tr
a
c
ti
o
n
 (
g
)
a
b
 
Figure 4.8 Effect of suramin 3x10-4 (a) and PPADS 10-5M (b) on the response to 
noradrenaline in rat aorta. Controls are shown in closed circles while drug treatment is 
shown as open circles. Each point represents the mean ± s.e.m. Suramin and PPADS 
had no significant effect on the contraction induced by NA. (P > 0.05, Student t-test, 
N=4). 
 
4.3.3.6. Effect of NF449 on noradrenaline-induced contraction in rat aorta 
NF449 at 10-7, 10-6 and 10-5M had no effect on the magnitude of NA-induced contraction 
in RA (Table 4.3) (Figure 4.9a, b, c). It also did not alter the sensitivity to NA in RA 
(Table 4.3) (Figure 4.9a, b, c). 
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Table 4.3 Effects of NF449 on NA-induced contraction in RA 
       Treatment Rmax(g)     Log EC50(M) 
Control 0.74 ± 0.07 -7.08 ± 0.27 
        NF449 10-7M 0.55 ± 0.06 -6.94 ± 0.22 
Control 1.07 ± 0.08 -6.92 ± 0 .18 
        NF449 10-6M 0.88 ± 0.06 -6.66 ± 0.15 
Control 0.99 ± 0.40 -7.09 ± 0.25 
         NF449 10-5M   0.78 ± 0.09 -7.03 ± 0.21 
      Data represent the mean ± s.e.m of 4 experiments 
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Figure 4.9 Effect of NF449 10-7 (a), 10-6 (b), and 10-5M (c) on the response to 
noradrenaline in rat aorta. Controls are shown as closed circles, while drug treatment is 
shown as open circles. Each point represents the mean ± s.e.m. (P > 0.05, Student t-test, 
N=4). 
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4.3.3.7. Effect of Apyrase on noradrenaline-induced contraction in rat 
aorta 
Apyrase (1U/M) did not alter the magnitude of NA-induced contraction or the 
sensitivity to NA in RA (Figure 4.10). The maximum response to NA was 0.75 ± 0.04g 
in control and 0.70 ± 0.05g in the presence of apyrase 1U/M (p > 0.05, Student’s paired 
t-test; N = 4), and log EC50 values were -6.73 ± 0.13 in the control and -6.49 ± 0.13 in 
the presence of apyrase 1U/M (p > 0.05, Student’s paired t-test; N=4) (Figure 4.10). 
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Figure 4.10 Effect of apyrase (1U/M) on the response to noradrenaline in the rat aorta. 
Controls are shown as closed circles, while drug treatment is shown as open circles. 
Each point represents the mean ± s.e.m. Apyrase had no significant effect on the 
contraction induced by NA. (P > 0.05, Student t-test, N = 4). 
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4.3.3.8. Effect of mefloquine on 5-HT and U46619 in the rat aorta 
In order to investigate the specificity of mefloquine, responses to 5-HT and U46619 
were obtained in the absence and presence of mefloquine (2x10-5M). Mefloquine 
reduced the maximum response and the sensitivity to 5-HT in the RA. The maximum 
response to 5-HT was reduced from 0.94 ± 0.12g in control to 0.32 ± 0.1g in the presence 
of mefloquine (2x10-5M) (p < 0.05, Student’s paired t-test; N = 5), log EC50 was -9.37 
± 0.17 in the absence and -9.08 ± 1.82 in the presence of mefloquine (p < 0.05, Student’s 
paired t-test) (Figure 4.11b). In addition, mefloquine (2x10-5M) abolished the response 
to U46619 in the RA. Rmax was 0.78 ± 0.11g in the absence and 0.07 ± 0.007g in the 
presence of mefloquine (P < 0.0001, Student t-test, N=4) (Figure 4.11b). 
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Figure 4.11 Effect of mefloquine (2x10-5M) on the responses to (a) 5-HT and (b) 
U46619 in rat aorta. Controls are shown as closed circles, while drug treatment is shown 
as open circles. Each point represents the mean ± s.e.m. Differences between Rmax 
values are shown by **P < 0.01, ****P < 0.0001 (Student’s paired t-test, N = 5). 
 
4.3.3.9. Effect of mefloquine and probenecid on KCl-induced contraction in 
rat aorta, while suramin has no effect 
The effects of mefloquine, probenecid and suramin on the contractile response to the 
maximm response of the extracellular KCl (60 mM) in RA were examined. Mefloquine 
(2x10-5M) and probenecid (2x10-6M) reduced the magnitude of KCl-induced 
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contraction in RA. The KCl-induced tone was reduced from 5.04 ± 9.8% in control to -
58.61 ± 16.90% in the presence of mefloquine 2x10-5M (p < 0.001, Student’s paired t-
test; N = 4) (Figure 4.12a). The KCl-induced tone was reduced from 5.04 ± 9.8% in 
control to -52.42 ± 15.53% in the presence of probenecid 3mM (p < 0.001, Student’s 
paired t-test; N = 5) (Figure 4.12b). Suramin did not alter the KCl-induced contraction 
in RA. The KCl-induced tone was 5.04 ± 9.8% in the absence and -14.61% ± 14.59% 
in the presence of suramin (3x10-4 M) (P > 0.05, Student’s paired t-test; N = 4) (Figure 
4.12c). 
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Figure 4.12. Effect of mefloquine (a), probenecid (b) and suramin (c) on KCl-
induced tone in rat aorta. Controls are shown as closed circles, while drug 
treatment is shown as open circles. Data are shown as a percentage of the 
contractions induced by KCl. Data are presented as the mean value ± s.e.m. (a) 
Mefloquine (2x10-5M) and (b) probenecid (2x10-3M) significantly decreased the 
contraction to KCl in rat aorta. Differences between Rmax values are shown by 
**P < 0.01, ***P < 0.001 (Student’s paired t-test, N = 5). (c) Suramin had no 
significant effect on the contraction to KCl (P > 0.05, Student’s paired t-test, N = 
5). 
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4.3.3.10. Effect of mefloquine (2x10-5M) on contraction to Ca2+ in the rat 
aorta 
The effect of three different concentrations of mefloquine (2x10-5, 2x10-6 and 2x10-7M) 
on the concentration-dependent contraction of Ca2+ (1x10-6 to 3x10-3M, in three-fold 
increments) re-added to Ca2+free buffer containing 60mM KCl was examined. 
Mefloquine at 2x10-5M reduced the magnitude of Ca2+-induced contraction in RA (P < 
0.001, One-way ANOVA). By contrast, lower concentrations of mefloquine (2x10-6 and 
2x10-7M) had no effect on the response to the re-addition of Ca2+ in RA (Figure 4.13). 
The maximum response to Ca2+ was reduced from 0.68 ± 0.1g in control to 0.03 ± 0.04g 
in the presence of mefloquine (2x10-5M) (p > 0.05, One-way ANOVA; N = 4) (Figure 
4.13a). The maximum responses to Ca2+ were 0.68 ± 0.1g in control and 0.7 ± 0.17g in 
the presence of mefloquine (2x10-6M) (p > 0.05, One-way ANOVA; N = 4) (Figure 
4.13). The maximum responses to Ca2+ were 0.68 ± 0.1g in control and 0.65 ± 0.09g in 
the presence of mefloquine (2x10-7M) (p > 0.05, One-way ANOVA; N = 4) (Figure 
4.13). 
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Figure 4.13 Effect of mefloquine (2x10-7,2x10-6and 2x10-5M) on the response to the re-
introduction of Ca2+ in rat aorta. Each point represents the mean ± s.e.m. Mefloquine at 
2x10-5M reduced significantly the maximum response to Ca2+ in rat aorta. Differences 
between Rmax values are shown by ***P < 0.001 (One-way ANOVA, N=4). Mefloquine 
at 2x10-6 and 2x10-7M did not alter the maximum response to Ca2+ (One-way ANOVA, 
N=4). 
 
4.4. Discussion 
The aim of the present study was to determine whether pannexin channels and ATP 
contributed to the response to NA in a preparation containing α1D–adrenoceptors, 
namely the rat aorta.  Western blot analysis showed the presence of both pannexin1 and 
pannexin2. Conflicting data were obtained using three different pannexin inhibitors, i.e. 
mefloquine (a non-selective pannexin inhibitor), probenecid (a pannexin1 inhibitor) and 
Brilliant Blue FCF (a pannexin1 inhibitor) (Beckel et al 2015). While mefloquine and 
probenecid decreased the response to NA, BB-FCF had no effect. The lack of effect of 
P2 purinoceptor antagonists, suramin, PPADs and NF449 argues against a possible role 
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for ATP acting via P2 receptors in contributing to the NA-induced α1D–adrenoceptor-
mediated response in the rat aorta. Further investigation of the effects of mefloquine 
indicated that it also inhibited responses to raised KCl, 5-HT and U46619 and calcium-
entry mechanisms suggesting that it produces non-selective actions and questions its use 
as a pannexin inhibitor. 
Western blot analysis showed that both pannexin1 and pannexin2 are present in RA. 
Pannexin 1 fluorescence indicated the presence of pannexin1 in the tunica media, 
although this was clouded by autofluoresence in the control samples. Similarly, 
pannexin1 and pannexin2 have been reported to be expressed in several tissues, 
including in the CNS, eye, prostate, thyroid, liver, and kidney. For example, in the 
hippocampus, both pannexin1 and pannexin2 were expressed in the pyramidal cell layer 
and in individual neurons in the stratum oriens and stratum radiatum, but pannexin3 
could only be detected in the skin. All 3 isoforms of pannexins are expressed in the 
pulmonary artery and alveoli. Pannexin1 is the predominant pannexin isoform in 
coronary arteries (except in arteries less than 100 μm) whereas pannexin3 is expressed 
in the juxtaglomerular apparatus and cortical arteriole. Billaud et al (2011) also showed 
that pannexin1 is expressed in vascular smooth muscle cells of TDA.  
Billaud et al (2011) suggested that there is an interaction between pannexin1 and α1D–
adrenoceptors. Mefloquine (10-20 µM) and probenecid (0.5-2 mM) inhibited 
phenylephrine-induced vasoconstriction, suggesting that pannexin1 and α1D ‒
adrenoceptor are intimately coupled – both are part of the same protein complex. The 
existence of α1D-adrenoceptors in rat aorta has been shown previously (Gisbert et al 
2000) based upon the functional activity of a selective α1D-adrenoceptor antagonist 
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(BMY 7378) which correlated with binding affinities for cloned α1D -adrenoceptors 
(Kenny et al 1995; Saussy et al 1996; Hussain and Marshall, 1997).  
In order to examine the involvement of pannexin in mediating the response to NA in 
RA (which contains both pannexin and α1D–adrenoceptors), the magnitude of NA-
induced contraction in RA were assessed in the presence of three pannexin inhibitors, 
i.e. mefloquine, probenecid, and BB-FCF. The results showed that while mefloquine 
and probenecid decreased the response to NA, BB-FCF had no effect. Mefloquine is a 
non-selective pannexin inhibitor. Probenecid has been shown to selectively block 
pannexin1 channels at concentrations up to 5 mM (Dando and Rorar, 2009; Lamkanfi 
et al 2009; Ransford et al 2009; Xia et al 2012; Silverman et al 2008), while BB-FCF 
has recently been shown to be a pannexin1 inhibitor (Beckel et al 2015; Wang et al 
2013).  
While mefloquine reduced responses to NA at three different concentrations (2 × 10-
7M, 2 × 10-6M and 2× 10-5M), only the highest concentration inhibited the KCl response. 
Similarly, whereas all concentrations of probenecid (2 × 10-5M, 2 × 10-4M and 2× 10-
3M) inhibited the NA-mediated contraction, only 2 × 10-3M inhibited KCl-induced tone. 
Such differences in the results obtained from different concentrations could be because 
mefloquine and probenecid produce non-selective inhibition of vascular responses at 
high concentrations. Indeed, evidence for non-selective actions of mefloquine are 
presented below. This suggests that mefloquine and probenecid should only be used at 
relatively low concentrations as pannexin1 inhibitors in order to investigate the role of 
pannexin channels in vasoconstriction. The results with low concentrations of 
mefloquine and probenecid could be taken as evidence that pannexin channels 
participate in α1-adrenoceptor-mediated vasoconstriction in the RA. However, even if 
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this were the case, there is no evidence to support the release of ATP through these 
channels to act as an intercellular messenger. 
Billaud et al (2011) proposed that phenylephrine–induced α1D‒adrenoceptor-mediated 
vasoconstriction is caused by release of ATP through pannexin channels, based upon 
the sensitivity of responses to phenylephrine to P2 purinoceptor antagonists. The current 
results, however, do not support the ‘α1-adrenoceptor– pannexin1 channel ATP release’ 
theory since P2 purinergic receptor antagonists (suramin, PPAD and NF449) and 
apyrase, an enzyme that breaks down ATP, had no significant inhibitory effect on NA-
induced vasoconstriction in RA. This indicates that ATP is not involved via P2 receptors 
in mediating the response to the NA activation of α1D–adrenoceptors in the rat aorta.  
The results of the present study are in agreement with Angus et al (2015) who reported 
that responses to phenylephrine, U46619, vasopressin, endothelin-1, sympathetic nerve 
stimulation and K+ were inhibited in rat and mouse small mesenteric arteries using 
mefloquine, Therefore, it has been argued that the release of ATP does not contribute to 
the contraction to phenylephrine after α1D-adrenoceptor activation. 
In the rat aorta, the effects of mefloquine indicated that it also inhibited responses to 
raised KCl, 5-HT and U46619. This confirms that mefloquine inhibits other agonist 
responses, possibly by inhibiting calcium-entry mechanisms. To investigate this further 
the present study showed that mefloquine, at high concentrations, blocked responses to 
the re-introduction of calcium into depolarised artery segments. Mefloquine has 
previously been reported to decrease L-type Ca2+ currents in single ventricular myocytes 
(Coker et al 2000), and so a similar mechanism is likely in the RA. It should be noted 
that inconsistent results have been reported in the literature regarding the influence of 
mefloquine on the responses to KCl with Billaud et al (2011) reporting that mefloquine 
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did not inhibit the response to KCl (40mM) in mouse TDA. Angus et al (2015) argued 
that mefloquine becomes a selective pannexin1 inhibitor only when used in 
concentrations lower than 0.1 μM. 
In conclusion, in rat aorta, there is no conclusive evidence that pannexin/ATP is 
involved in α1D–adrenoceptor-mediated responses in RA (which expresses both 
pannexin1 and α1D-adrenoceptors). This indicates that the assumption reported by 
Billaud et al (2011) that pannexin1 is associated with α1D-adrenoceptors (i.e. pannexin1 
opens to release purines that act on purinergic receptors present on smooth muscle cell  
leading to enhanced vasoconstriction) is questionable. 
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Chapter 5  
 
5. Role of pannexin channels in mediating endothelium-dependent 
vasorelaxation in porcine splenic artery and porcine coronary 
artery 
5.1. Introduction 
Cell-to-cell communication provides coordination of cellular processes in multicellular 
organisms. In the vascular system, the mechanisms underlying the multilayer 
communication between cells of different types include gap junctions (de Wit and 
Griffith, 2010, de Wit and Griffith, 2010, Paul, 1986, Burnstock and Ralevic, 2013) and 
paracrine action of signalling molecules, such as ATP (Burnstock and Ralevic 2014). 
Gap junctions are part of the connexin family of proteins that connect the cytoplasm of 
neighbouring cells by forming a transmembrane channel allowing ions and small 
molecules to pass through the channel. The gap junction proteins in invertebrates has 
the same function but differs in structure. This family of specific invertebrate gap 
junction proteins was designated as innexins (Phelan et al 1998). After innexins 
homologs were discovered in humans and other vertebrates, it was proposed to 
reclassify them along with their vertebrate homologs into a bigger family, named 
pannexins (Panchin et al 2000; Baranova et al 2004). Mammalian pannexins form 
hemichannels implicated in the release of ATP and other small molecules from the 
cytoplasm into the extracellular environment (Bruzzone et al 2003; Ishikawa et al 2011).  
Since pannexins are involved in intercellular communication that is essential for the 
functioning of the vascular system (de Wit and Griffith 2010), the presence (or absence) 
of pannexins may play an important role in blood flow regulation. Blood vessels contain 
two major functional components smooth muscle and endothelium. The endothelium 
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facilitates vasodilator effects of many blood-circulating hormones and locally acting 
autacoids (Vane , et al1994). In murine arteries pannexin1 is the primary expressed 
isoform (Lohman, et al 2012). Pannexin1 is  present in endothelium of most arteries 
(Lohman et al 2012) and capillaries (Shestopalov and Panchin 2008), however the 
pattern of pannexin1 expression depends on the vessel size. In contrast to larger conduit 
arteries where pannexin1 is expressed primarily in the endothelium, in smaller 
resistance arteries it is also expressed in smooth muscle (Lohman et al 2012). In 2014 
Dina et al studied the functional role of pannexin1 in facilitating vasodilator and 
anticontractile effects of the endothelium and suggested a major role for pannexin1in 
endothelium-dependent responses. They utilized pannexin1−/− mice as a test model for 
investigating the functional significance of pannexin1 and found that endothelial 
function was impaired in conduit arteries of pannexin1 knockout mice. In particular, 
they demonstrated that the EDHF component of endothelium-dependent responses was 
impaired in pannexin1 knockout mice. The aim of this study was to determine whether 
pannexins were involved in contributing to endothelium-dependent responses in two 
conduit arteries isolated from pigs, namely, the splenic artery and coronary artery. 
 
5.2. Materials and methods 
5.2.1. Western blotting  
Porcine hearts were collected from the abattoir and processed as described in section 
2.3. Samples were run on 7% SDS-PAGE gels using a Biorad Mini-protein 3 system as 
described in section 2.3. Subsequently, the nitrocellulose membrane was incubated 
overnight with the primary antibody with Rabbit anti-pannexin1 (Abcam cat No. 
ab124969) at 4°C , Rabbit anti-pannexin2 (Abcam cat No. ab55917)  and  Rabbit anti-
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pannexin 3 (Abcam cat No. ab98093) at 1:1000 concentration in 5% (w/v) milk solution 
using and mouse monoclonal anti-GAPDH antibody (G8795 Sigma-Aldrich) (1:40 000) 
followed by incubation with appropriate secondary antibodies IRDye® 680LT  Goat 
anti-mouse IgG (1:10 000) (LI-COR Biosciences, Cambridge, UK) and IRDye® 
800CW Goat anti-rabbit IgG (1:10 000) (LI-COR Biosciences, Cambridge, UK) for 1 
hour at room temperature. After that membranes were analysed using Li-Cor Odyssey 
Imager Scanner and densities of the bands were determined using Odyssey. 
 
5.2.2. Immunohistochemistry 
5.2.2.1. Paraffin embedding tissue and sectioning 
Porcine coronary arteries were dissected from the heart and processed as described in 
section 2.4.1. Immunohistochemistry experiment was performed as described in section 
2.4.1. The primary antibodies were diluted in (PBS 0.1%, 0.1% Tween-20, 1%BSA) to 
a dilution of 1:500. And incubated overnight, while the secondary antibody, Rodamine 
Red conjugate (R-6394), was diluted to 1:1000 and applied to the sections for 1 h. 
Following this they were incubated with DAPI (1in 500 dilution) for 5 min in the dark. 
Coverslips were applied using mounting medium (1% (v/v) 1, 4-diazobicyclo-[2, 2, 2,]-
octane (DABCO) fluorescence mounting medium-SS04. The slides were examined at 
20 and 40 magnification using microscope to assess pannexin location. The following 
filters were used to visualise the immunostains; DAPI excitation 350/50nm, emission 
460/50 nm, Rhodamine Red - Excitation 545/20nm, emission 610/75 nm for the Goat 
anti-rabbit IgG (H+L) secondary antibody. 
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5.2.3. Isometric tension 
5.2.3.1. Tissue collection and sample preparation 
Porcine splenic and coronary arteries (PSA and PCA) were dissected cut into 4 equal 
strips approximately 5mm in length as described in section 2.5. 
 
5.2.3.2. Isometric tension recording 
PSA and PCA were collected and processed as described in section 2.5. Briefly, 
following the addition of KCl twice, U46619 (1nM – 90nM) was employed to increase 
vascular tone to 50% of the KCl response. Once stable tone was achieved, 
concentration-response curves to bradykinin (10-10 - 3X10-6M) were constructed. 
Vasorelaxation to bradykinin was studied in PSA in the presence of the pannexin1 
channel inhibitors mefloquine (2x10-7, 2x10-6, 2x10-5M) and probenecid (2x10-4, 2x10-
5M) and compared to the control tissue. 
Vasorelaxation to bradykinin was also studied in the presence of NG-nitro-L-arginine 
methyl ester (L-NAME) (10-4M)), a NO synthase inhibitor, to determine the NO-
mediated component (Randall &Griffith, 1991). Indomethacin (10-5M) was used to 
inhibit the synthesis of prostanoids and in the presence of (L-NAME) (10-4M) and 
indomethacin (10-5M) together, compared to the control segment.  
Thereafter responses to bradykinin were studied in PCA in the absence or presence of 
the reportedly selective pannexin1 channel inhibitors mefloquine (2x10-7, 2x10-6, 2x10-
5M) probenecid (3x10-7, 3x10-6, 3x10-5M) and carbenoxolone (10-4M) in preparations 
exposed toboth L-NAME (10-4M) and indomethacin (10-5M) together to isolate the 
EDHF component of the response to Bradykinin. 
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5.2.4. Statistical analysis 
Statistical analysis was conducted as described in section 2.6. The relaxation to 
bradykinin was measured from the stabilised U46619-induced response and was 
expressed as a percentage of the U46619-induced contraction. Data were expressed as 
log concentration response curves. Values for all figures refer to mean ± s.e.m with 95% 
confidence. 
5.3. Results 
5.3.1. L-NAME and the combination of L-NAME and indomethacin 
decreased the vasorelaxation to bradykinin in porcine splenic 
artery 
Bradykining induced concentration-dependent relaxation in PSA (Figure 5.1a). L-
NAME (10-4M) and the combination of L-NAME (10-4M) and indomethacin (10-5M) 
significantly decreased the relaxation to bradykinin in PSA, while indomethacin (10-
5M) alone did not affect bradykinin-induced vasorelaxation in PSA. The maximum 
response to bradykinin was -83.62 ± 8.44% (control) and -25.79± 6.48% in the presence 
of L-NAME (10-4M) (P<0.05, one way ANOVA, N = 6), the sensitivity was -9.09± 0.39 
(control) and -8.56± 0.2 (L-NAME (10-4M)) (P>0.05, one way ANOVA) (Figure 5.1b). 
The maximum response to bradykinin was -83.62 ± 8.44% (control) and -81.19± 
12.88% in the presence of indomethacin (10-5M) (P>0.05, one way ANOVA, N = 6), 
the sensitivity was -9.09 ± 0.39 (control) and -8.77± 0.60 (indomethacin (10-5M)) 
(P>0.05, one way ANOVA) (Figure 5.1). The maximum response to bradykinin was -
83.62 ± 8.44% (control) and -20.34 ± 7.13% in the presence of L-NAME (10-4M) and 
indomethacin (10-5M) (P<0.05, one way ANOVA, N = 6), the sensitivity was -9.09± 
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0.39 (control) and -8.74± 0.44 (L-NAME and indomethacin) (P>0.05, one way 
ANOVA) (Figure 5.1b).  
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Figure 5.1 (a) Representative trace showing the vasorelaxation-induced by bradykinin 
in porcine splenic artery. (b) Effect of L-NAME (10-4M) and indomethacin (10-5M) and 
their combination on the response to bradykinin in the porcine splenic artery. The 
relaxation caused by bradykinin was expressed as a percentage of U46619-induced 
contraction. Each point represents the mean ± s.e.m, N=6. Differences between Rmax 
values are shown by *P < 0.05 (one way ANOVA). 
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5.3.2. The effect of mefloquine on bradykinin-induced vasorelaxation in 
porcine splenic artery 
Mefloquine, used at three different concentrations; 2x10-7, 2x10-6 and 2x10-5M did not 
alter the relaxation to bradykinin in PSA.  The U46619 concentration used was 
significantly higher in the presence of mefloquine to produce the target tone (50-70% 
of the second KCl response). In the control tissue the concentration of U46619 used 
ranged from 10-9 and 10-7M while in the presence of mefloquine concentrations as high 
as 10-6M were required. 
 
The maximum response to bradykinin was -51.72 ± 7.80% (control) and -57.87 ± 
25.69% in the presence of mefloquine (2x10-7M) (P>0.05, One-way ANOVA, N = 6), 
the sensitivity was -8.78± 0.32 (control) and -8.156 ± 0.52 (mefloquine (2x10-7M)) 
(P>0.05, One-way ANOVA) (Figure 5.2). The maximum response to bradykinin was -
51.72 ± 7.806% (control) and -65.90 ± 9.84% in the presence of mefloquine (2x10-6M) 
(P>0.05, One-way ANOVA, N = 6), the sensitivity was -8.785 ± 0.32 (control) and -
7.85 ±1.41 (mefloquine (2x10-6M)) (P>0.05, One-way ANOVA) (Figure 5.2). The 
maximum response to bradykinin was -51.72 ± 7.806% (control) and -58.84 ± 10.27% 
in the presence of mefloquine (2x10-5M) (P>0.05, One-way ANOVA, N = 6), the 
sensitivity was -8.785 ± 0.32 (control) and -8.50 ± 0.24 (mefloquine (2x10-5M)) 
(P>0.05, One-way ANOVA) (Figure 5.2). 
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Figure 5.2 Effect of mefloquine (2x10-7, 2x10-6 and 2x10-5M) on the response to 
bradykinin in the porcine splenic artery. The relaxation caused by bradykinin was 
expressed as a percentage of U46619-induced contraction. Each point represents the 
mean ± s.e.m, N=6. Mefloquine did not alter the relaxation to bradykinin in porcine 
splenic artery (One-way ANOVA). 
 
5.3.3. The effect of probenecid on bradykinin-induced vasorelaxation in 
porcine splenic aretry 
Probenecid, used at two different concentrations; 2x10-5, 2x10-4M did not alter the 
relaxation-induced by bradykinin in PSA. The maximum response to bradykinin was -
54.29 ± 4.50% (control) and -50.38 ± 7.25% in the presence of probenecid (2x10-5M) 
(P>0.05, one way ANOVA, N = 7), the sensitivity was -8.35 ± 0.24 (control) and -8.21 
± 0.46 (probenecid (2x10-5M)) (P>0.05, one way ANOVA) (Figure 5.3). The maximum 
response to bradykinin was -54.29 ± 4.50% (control) and -50.18 ± 5.03% in the presence 
of probenecid (2x10-4M) (P>0.05, one way ANOVA, N = 7), the sensitivity was -8.35± 
0.24 (control) and -8.32± 0.29 (probenecid (2x10-4M)) (P>0.05, one way ANOVA) 
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(Figure 5.3). When using 2x10-3M probenecid, it was not possible to produce a sustained 
contraction with U46619. 
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Figure 5.3 Effect of probenecid (2x10-5 and 2x10-4M) on the response to bradykinin in 
the porcine splenic artery the relaxation caused by bradykinin was expressed as a 
percentage of U46619-induced contraction. Each point represents the mean ± s.e.m, 
N=7. Probenecid did not alter the relaxation to bradykinin in porcine splenic artery (one 
way ANOVA). 
 
Since there was no evidence for a large consistent EDHF response in the PSA, 
subsequent studies were attempted using the porcine coronary artery. 
 
 
5.3.4. Pannexin1, pannexin 2 and pannexin 3 expression in porcine 
coronary artery 
The expression of pannexin1 and pannexin2 was shown as a 50 kDa and 100 kDa bands 
respectively, in all samples of PCA. The lanes show coronary artery samples from 7 
different pigs. The 50 kDa bands observed during western blotting correspond to 
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pannexin1 protein (http://www.abcam.com/pannexin-1-antibody-EPR5556-ab124969-
references.html).While the 100 kDa bands correspond to pannexin2 
(http://www.abcam.com/pannexin-2-antibody-ab55917-references.html) .In addition, 
the expression of pannexin3 (http://www.abcam.com/pannexin-3-antibody-
ab98093.html) was examined using anti-pannexin3 antibody, but the expression of 
pannexin3 was not evident in PCA as we did not detect a band corresponding to 
pannexin3 (Figure 4.5). 
 
 
 
Figure 5.4 Western blot analysis to determine pannexin1, pannexin2 and pannexin3 
expression in porcine coronary artery. N = 7.  
 
 
5.3.5. Pannexin1 expression assessed by immunohistochemistry in 
porcine coronary artery 
Immunolabelling of pannexin1 was carried out using anti-pannexin1 specific antibody, 
and a cross section of endothelium and smooth muscle cells of porcine coronary artery 
labelled for the presence of pannexin1 was visualised under a light microscope and a 
fluorescence microscope X20 and X40 magnifications. The image shows expression of 
pannexin1 in the endothelium and the smooth muscle cells of PCA (Figure 5.5). 
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Figure 5.5. Light microscopic images of porcine coronary artery at X20 in the absence 
of a primary antibody (a) stained without primary antibody. Expression of pannexin1 
shown by immunohistochemistry in the absence (b) and presence (c) of anti-pannexin1 
specific antibody at X20. Expression of pannexin1 shown by immunohistochemistry in 
the absence (d) and presence (e) of anti-pannexin1 specific antibody at X40. Expression 
was evident in the endothelium and the smooth muscle cells of porcine coronary artery. 
N =6. 
 
 
5.3.6. L-NAME and the combination of L-NAME and indomethacin 
decreased the vasorelaxation to bradykinin in porcine coronary artery 
 
L-NAME (10-4M) and the combination of L-NAME (10-4M) and indomethacin (10-5M) 
significantly decreased the relaxation to bradykinin in PCA, while indomethacin (10-
5M) alone did not affect bradykinin -induced vasorelaxation in PCA. The maximum 
response to bradykinin was -80.27 ± 7.02% (control) and -25.15 ± 4.76% in the presence 
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of L-NAME (10-4M)  (P<0.001, one way ANOVA, N = 6), the sensitivity was -7.69 ± 
0.21 (control) and -8.0± 0.2 (L-NAME (10-4M)) (P>0.05, one way ANOVA) (Figure 
5.6). The maximum response to bradykinin was -80.27 ± 7.02% (control) and -68.65 ± 
2.88% in the presence of indomethacin (10-5M) (P>0.05, one way ANOVA, N = 6), the 
sensitivity was -7.69 ± 0.21 (control) and -8.06 ± 0.56 (indomethacin (10-5M)) (P>0.05, 
one way ANOVA) (Figure 5.6). The maximum response to bradykinin was -80.27 ± 
7.02% (control) and -36.08 ± 4.8% in the presence of L-NAME (10-4M) and 
indomethacin (10-5M) (P<0.001, one way ANOVA, N = 6), the sensitivity was -7.69 ± 
0.21 (control) and -8.14 ± 0.11 (L-NAME and indomethacin) (P>0.05, one way 
ANOVA) (Figure 5.6). 
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Figure 5.6 Effect of L-NAME (10-4M) and indomethacin (10-5M) and their combination 
on the response to bradykinin in the porcine coronary artery. The relaxation caused by 
bradykinin was expressed as a percentage of U46619-induced contraction. Each point 
represents the mean ± s.e.m, N=6. Differences between Rmax values are shown by *** P 
< 0.001 (one way ANOVA). 
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5.3.7. The effect of probenecid, carbenoxolone and mefloquine on 
bradykinin-induced vasorelaxation in porcine coronary artery 
Mefloquine (2x10-5M) decreased the relaxation to bradykinin, while probenecid (2x10-
3M) and carbenoxolone (10-4M) did not affect bradykinin-induced vasorelaxation in 
PCA. The maximum response to bradykinin was -71.87± 9.54% (control) and -45.60 ± 
6.48% in the presence of mefloquine (2x10-5M) (P<0.001, one way ANOVA, N = 6), 
the sensitivity was -7.79 ± 0.24 (control) and -7.1 ± 3.4 (mefloquine (2x10-5M)) (P>0.05, 
one way ANOVA) (Figure 5.7). The maximum response to bradykinin was -71.87± 
9.54% (control) and -69.03 ± 5.67% in the presence of probenecid (2x10-3M) (P>0.05, 
one way ANOVA, N = 6), the sensitivity was -7.79± 0.24 (control) and -8.26 ± 0.16 
(probenecid (2x10-3M)) (P>0.05, one way ANOVA) (Figure 5.7). The maximum 
response to bradykinin was -71.87 ± 9.54% (control) and -78.52 ± 6.21% in the presence 
of carbenoxolone (10-4M) (P>0.05, one way ANOVA, N = 6), the sensitivity was -7.79 
± 0.24 (control) and -8.26± 0.14 (carbenoxolone (10-4M) (P>0.05, one way ANOVA) 
(Figure 5.7). 
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Figure 5.7 Effect of mefloquine (2x10-5M), probenecid (2x10-3M) and carbenoxolone 
(10-4M) on the response to bradykinin in the porcine coronary artery. The relaxation 
caused by bradykinin was expressed as a percentage of U46619-induced contraction. 
Each point represents the mean ± s.e.m, N=6. Differences between Rmax values are 
shown by *** P < 0.001 (one way ANOVA). 
 
 
5.3.8. The effect of probenecid, carbenoxolone and mefloquine on 
bradykinin-induced vasorelaxation in porcine coronery artery in the 
presence of L-NAME and indomethacin 
Following treating the PCA with L-NAME (10-4M) and indomethacin (10-5M), 
mefloquine (2x10-5M) decreased the relaxation to bradykinin, while probenecid (2x10-
3M) and carbenoxolone (10-4M) did not affect bradykinin-induced vasorelaxation in 
PCA. The maximum response to bradykinin was -52.18 ± 8.07% (control) and -16.76 ± 
3.5% in the presence of mefloquine (2x10-5M) (P<0.01, one way ANOVA, N = 6), the 
sensitivity was -7.59 ± 0.25 (control) and -6.77 ± 0.61 (mefloquine (2x10-5M)) (P>0.05, 
one way ANOVA) (Figure 5.8). The maximum response to bradykinin was -52.18 ± 
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8.07% (control) and -44.18 ± 8.70% in the presence of probenecid (2x10-3M) (P>0.05, 
one way ANOVA, N = 6), the sensitivity was -7.59± 0.25 (control) and -7.77± 0.37 
(probenecid (2x10-3M)) (P>0.05, one way ANOVA) (Figure 5.8). The maximum 
response to bradykinin was -52.18 ± 8.07% (control) and -43.30± 7.34% in the presence 
of carbenoxolone (10-4M) (P>0.05, one way ANOVA, N = 6), the sensitivity was -7.59± 
0.25 (control) and -7.74 ± 0.32 (carbenoxolone (10-4M)) (P>0.05, one way ANOVA) 
(Figure 5.8). 
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Figure 5.8 Effect of mefloquine (2x10-5M), probenecid (2x10-3M) and carbenoxolone 
(10-4M) on the response to bradykinin in the porcine coronary artery in the presence of 
L-NAME and indomethacin. The relaxation caused by bradykinin was expressed as a 
percentage of U46619-induced contraction. Each point represents the mean ± s.e.m, 
N=6. Differences between Rmax values are shown by ** P < 0.01 (one way ANOVA). 
 
 
                                                                     132 
 
5.4. Discussion 
Although pannexin 1 has been shown previously to participate in endothelium-
dependent vasodilation in pannexin1 knockout mice (Gaynullina et al 2014), the exact 
mechanism by which pannexin1 exerts its role remains speculative. This work addresses 
the theory that pannexin1 induces large vessel relaxations by regulating endothelium-
derived hyperpolarization (EDH)-like mechanisms. The results showed that non-
prostanoid non-nitric oxide component was involved in the bradykinin-mediated 
relaxation .Such experiments usually indicate the presence of an  EDH- component of 
bradykinin-induced relaxation in porcine coronary arteries, studied after inhibition of 
NO-synthase and cyclooxygenase, was largely unaffected by pannexin inhibitors. 
In PSA, bradykinin caused only a modest concentration-dependent relaxation in 
preparations exposed to L-NAME and indomethacin, indicating there was not much 
evidence for the presence of an EDH response whilst in the PCA, bradykinin caused a 
more consistent and slightly larger concentration-dependent relaxation in preparations 
exposed to L-NAME and indomethacin, indicating the possible presence of an EDH 
element in the response. Overall, the use of three different pannexin inhibitors produced 
conflicting effects. In the PSA, there was no evidence for an inhibitory action of 
pannexin inhibitors on bradykinin responses. In the PCA, the overall response showed 
that mefloquine inhibited the response to bradykinin, while probenecid and 
carbenoxolone had no effect on bradykinin .When the EDHF response was isolated, 
mefloquine reduced the bradykinin-induced EDHF response, while probenecid and 
carbenoxolone had no effect. 
Studying the participation of pannexin1 in EDH mechanisms is of interest because it 
has been previously reported that the released of ATP from endothelial cells led to 
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vasorelaxation in an EDH-like manner (Kwon, 2001). Additionally, pannexins have 
been shown to form ATP-permeable ‘hemichannels’ or ‘functional gap junctions’ in 
some cell types (Bruzzone et al 2003; Ishikawa et al 2011; Sahu et al 2014; Dahl and 
Muller, 2014; Penuela et al 2012); such hemichannels may play a role in the EDH-like 
relaxation.  
Pannexin1 mRNA has been shown to localize largely to endothelial cells of the murine 
saphenous artery (Gaynullina et al 2014). The existence of pannexin1 in endothelium 
was also established by immunohistochemistry in saphenous artery whole mounts; when 
pannexin1 was knocked out there was no compensatory up-regulation of pannexin2 or 
pannexin3.  
Gaynullina et al (2015) reported that purinergic signalling is responsible for a 
considerable portion of the EDH-like response in the saphenous artery, since 
purinoceptor antagonists and apyrase significantly reduced EDH-like relaxations in wild 
type (WT) animals. Furthermore, knocking out pannexin1 protein reduced the presence 
of an EDHF response in the saphenous artery. They proposed the model presented in 
Figure 5.9. 
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Figure 5.9 Diagram showing mechanisms of pannexin1 involvement in the functioning 
of EDHF-like mechanism during agonist-induced stimulation followed by smooth 
muscle relaxation. Intermediate conductance calcium activated potassium channels 
(IKCa) – endothelial intermediate conductance calcium-activated potassium channels; 
SKCa – small conductance calcium-activated potassium channels; R – receptor; ACh – 
acetylcholine; Ado – adenosine; ER – endoplasmic reticulum; IP3R – 1,4,5-inositol 
trisphosphate receptor; EC – endothelial cell; IEL – internal elastic lamina; SMC – 
smooth muscle cell; MEGJ – myoendothelial gap junctions; GJ – gap junctions; KIR – 
inwardly rectifying potassium channels. Adapted from Gaynullina et al 2015. 
 
They proposed a possible mechanism involving the signalling of adenosine (triggered 
by ATP hydrolysis into adenosine). The extracellular ATP is hydrolysed to adenosine, 
which could bind to P1 receptors leading to vessel dilation. Additionally, it is recognised 
that extracellular ATP can stimulate P2Y receptors on endothelial cell surfaces, thus 
activating a supplementary increase in intracellular cytoplasmic Ca2+ (Yamamoto et al 
2003) and further potentiating pannexin1-hemichannels (Locovei et al 2006). An 
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increase in cytoplasmic Ca2+ concentration is then expected following signalling 
pathways downstream of P1 receptors and P2 receptors, leading to an increase in the 
activation of intermediate conductance calcium activated potassium channels (IKCa) and 
calcium-sensitive potassium (KCa) channels and hyperpolarization of the endothelial 
cell. The resultant hyperpolarizing signal is then communicated to adjacent smooth 
muscle cells through the myoendothelial gap junctions or by the release of K+ through 
intermediate conductance calcium activated potassium channels (IKCa). Gaynullina et 
al (2015) confirmed that the EDH-like components of ACh-induced relaxation are 
impaired in the absence of pannexin1.  
The results from the present study indicate this is not a universal function of pannexins. 
In the PSA, responses to bradykinin were unaffected by three inhibitors that are known 
to act on pannexins, mefloquine, probenecid and carbenoxolone. There was only a small 
and inconsistent EDHF response in the PSA as evidenced by the response to bradykinin 
that remained after treatment with L-NAME and indomethacin. In the PCA, mefloquine 
reduced response to bradykinin, both under normal conditions and when an EDHF 
response was isolated. This could be taken as evidence that pannexins are involved in 
mediating the EDHF response consistent with Gaynullina et al (2015). However, 
probenecid and carbenoxolone had no effect on responses to bradykinin under either 
condition. Thus, overall, there is limited evidence to suggest that pannexins contribute 
to endothelium-dependent responses in either the PSA or the PCA. Interestingly, the 
lack of effect of carbenoxolone also indicates that the EDHF response in the PCA does 
not involve gap junctions (Gaynullina et al 2015).  The mechanism of the EDHF 
response in the PCA is unknown and it might be speculated what other substance could 
affect the EDHF component in PCA such as K+, H2O2 and hydrogen sulphide. 
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5.5. Conclusion 
The data using three different pannexin inhibitors shows that there is no evidence to 
suggest pannexin channels are involved in mediating endothelium-dependent 
vasorelaxation in porcine splenic or coronary arteries. 
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Chapter 6  
6. General discussion  
Pannexin members (pannexin1, pannexin2, and pannexin3) are recently discovered 
membrane proteins present in in mammalian genomes (Bond and Naus, 2014; Panchin, 
2000). The present study showed both pannexin1 and pannexin2 to be expressed in the 
PSA, PCA and RA. Immunolabelling of transverse sections of PSA, PCA and RA 
showed pannexin1 expression in both endothelial and smooth muscle cells. This is 
consistent with the observations of Billaud et al (2011) who provided evidence for the 
first time for a role of pannexin1 within the vasculature. They also used Western blotting 
and immunolabelling techniques to show pannexin1 to be expressed in endothelial cells 
and on the vascular smooth muscle cells in mouse TDA. They also showed 
colocalization of α1D–adrenoceptors and pannexin1 antibodies. Additionally, 
coimmunoprecipitation from TDA lysates confirmed the association of α1D–
adrenoceptors and pannexin1. Immune–scanning electron microscopy techniques 
showed pannexin1 to be expressed in the plasma membrane of arterial smooth muscle 
cells of the murine systemic arterial network (aorta, carotid artery, femoral artery, renal 
artery, TDA, abdominal arteries, arterioles in the spinotrapezius muscle, and cremasteric 
arterioles). Throughout the arterial tree, pannexin1 was the only protein detected and 
was consistently expressed in endothelium regardless of artery size. In large arteries, 
pannexin1 is only present in endothelial cells. However, the expression of pannexin1 in 
smooth muscle cells was poorly detectable in larger conduit arteries 
(aorta/carotid/femoral). Some expression of pannexin1 in smooth muscle cells was 
detected in renal arteries, whereas in smaller arteries including TDA, abdominal artery, 
spinotrapezius arterioles and cremasteric arterioles, pannexin1 was found throughout 
the smooth muscle. Similar to the smaller systemic arteries, both small (luminal 
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diameter of 20–90 μm) and large (luminal diameter of 100–250 μm) coronary arteries 
also expressed pannexin1 in endothelium and smooth muscle cellsand no pannexin2 
expression. Interestingly, in coronary arteries with a luminal diameter less than 100 μm, 
pannexin3 was detected in endothelium and smooth muscle (Lohman et al 2012). 
Pannexin1 channel was shown to have a role in the spread of contractile responses 
through vascular smooth muscle cell by acting as a cation/small molecule channel, a 
mechanism that resembles how pannexin1 channels act within the CNS (Thompson, 
2006). Pannexins have previously been shown to mediate paracrine intercellular 
communication through the release of purines (e.g. ATP or UTP). Recently, Billaud et 
al (2011) provided, for the first time, evidence for the expression and function of 
pannexin1 in the vasculature, in the thoracodorsal resistance arteries. The mechanism 
proposed include the phenylephrine-induced activation of α1-adrenoceptors, leading to 
the release of ATP through pannexin1 channels, leading to vasoconstriction on 
neighbouring smooth muscle cells through the activation of P2 receptors. It has been 
concluded that pannexins may coordinate vascular smooth muscle cell constriction and 
thereby blood pressure regulation via the activation of purinergic receptors and the 
release of purines. Their evidence used chemical inhibitors including mefloquine and 
probenecid, but also knockout mice. 
Billaud et al (2011) suggested that responses to noradrenaline involved pannexins in the 
TDA in mice. They showed that phenylephrine-induced contraction could be inhibited 
in the presence of pannexin1 inhibitors (mefloquine 10µM and 20µM (Lglesias et al 
2010), probenecid (500µM and 300µM) (Pelegrin and Supernat, 2006) and pannexin1 
peptide (200-300µM) (Billaud et al 2011). All of these pannexin inhibitors caused a 
significant decrease in phenylephrine-induced contraction. In addition, the purine-
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degrading enzyme apyrase (1U/ml and 10 U/ml), and purinergic receptor antagonists 
(suramin 100µM and 300 µM) and reactive blue-2 (75µM and 100µM) (a compound 
that they claim is a known inhibitor of P2Y purinergic receptors) also altered α1D.-
adrenoceptor-mediated responses in the mouse TDA (Billaud et al 2011). Billaud et al 
also showed that overexpression of pannexin1 caused an increased contractile response 
to phenylephrine. 
This encouraged them to speculate that phenylephrine binds to α1D-adrenoceptors 
causing the release of ATP through pannexin channels, in turn causing contraction. This 
ATP acts as an intercellular messenger on purinergic PY2 receptors and causes 
contraction of the blood vessel. This proposed joint mechanism is demonstrated in 
Figure 1.7, which has been illustrated as an adaptation from Billaud et al 2011. 
However, the concurrent stimulation of P2X receptors by ATP was not ruled out as 
suramin is a known P2X receptor antagonist and significantly reduced the 
phenylephrine-induced contraction. Furthermore, the selectivity of reactive blue-2 for 
the P2Y receptor has been questioned (Glazel et al 2003). Therefore, there is not strong 
evidence about which purinergic receptors subtype is implicated in this response. 
Billaud et al conducted an electroporation of thoracodorsal resistance arteries with either 
pannexin1-green fluorescent protein or pannexin1 small interfering RNA and showed 
enhanced and decreased constriction, respectively. TDA were transfected either with 
pannexin1-green fluorescent protein or with pannexin1 small interfering RNA. When 
pannexin1 was overexpressed, the response of TDA to phenylephrine was increased by 
approximately30%, whereas under expression of pannexin1 induced a 45%decrease in 
constriction in response to phenylephrine. Also, transfection of TDA with control small 
interfering RNA did not affect phenylephrine-induced constriction. Immunolabeling of 
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transfected TDA revealed that pannexin1 expression was modified only in vascular 
smooth muscle cell and not in ECs (Billaud et al 2011).   
Mefloquine is a drug that has been used clinically for the prevention and treatment of 
malaria.  It does so by targeting the F (0) complex of the F (0) F (1) H (+)-ATPase 
(Martin et al 2002).   Recently, Angus et al (2015) studied the specificity of melfloquine 
for pannexin1 by comparing the effect of mefloquine and carbenoxolone (a pannexin1 
inhibitor) on the contractile responses in mesenteric and TDA of mice and rats. Angus 
et al (2015) argued that pannexin1 has no role in α1-adrenoceptor mediated smooth 
muscle contraction, since mefloquine and carbenoxolone, at concentrations as low as 
1µM, had no effect on the responses to phenylephrine and KCl. However, when 
mefloquine was used at a higher concentration (3-10 µM), it showed a non-selective 
inhibitory effect towards the responses to phenylephrine, U46619, vasopressin, 
sympathetic nerve stimulation and to KCl (40mM), carbachol and CaCl2 induced 
contraction. This suggests that mefloquine becomes a non-selective inhibitor at 
concentrations above 1 µM. It has also been suggested that mefloquine inhibits Ca2+ 
channels in addition to being an anticholinergic (Unekwe et al 2010). Additionally, 
mefloquine has been shown to inhibit K+ channels leading to prolonged cardiac 
repolarization (Borsini et al 2012). 
In agreement with the Angus study the present study suggests that the use of mefloquine 
as a pannexin inhibitor is questionable because mefloquine (10–20 μM) produced a wide 
range of inhibitory actions, including inhibitory effects towards the contractions 
mediated by NA,U46619, sympathetic nerve stimulation, K+ (40 mM), 5-HT, U46619, 
and L-type Ca++ channel-mediated responses. 
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Probenecid is a drug that has been used clinically for the long-term management of gout 
due to its inhibitory effect on the renal tubular transporter, a transporter that blocks the 
uptake of uric acid (Ballerini et al 2002). The literature also reports its effect on different 
transporters in different cells. For example, probenecid has been shown to inhibit ATP 
binding cassette (Ballerini et al 2002) but to selectively inhibit pannexin channels with 
no effect on connexin-based channels (Silverman et al 2008). The present study showed 
probenecid inhibited NA-induced contractile responses in both the PSA and the RA, 
possibly suggesting that pannexin1 and α1A‒adrenoceptors are coupled in the PSA and 
pannexin1 and α1D‒adrenoceptors are coupled in the RA. Although probenecid was also 
shown to inhibit KCl responses in this study, there was a degree of selectivity in that 
2x10-5Mand 2 x10-4M affected the NA-mediated contraction, but had no effect on KCl 
responses, while higher concentrations (2 × 10-3M) affected both in RA.The mode of 
action and the mechanism by which probenecid inhibitors bind/affect to pannexin 
proteins are not clear, although it has been suggested that probenecid is water-soluble 
and thus it could interact with the hydrophilic part of the receptor protein (Silverman et 
al 2008). 
Carbenoxolone is classified as a specific pannexin1 channel inhibitor (Alexander et al 
2011, Pooenima et al 2011). Carbenoxolone (100 μM) has been shown to inhibit the 
hypotonically induced ATP release from human erythrocytes (Sridharan et al 2010). 
However, it was shown to have no effect on agonist or nerve-induced activation of 
alpha-adrenoceptors in rat small mesenteric resistance arteries (Angus et al 2015). The 
present study also showed carbenoxolone to have no effect on NA-induced contractile 
responses in the PSA, providing evidence against a role for pannexins in the PSA. 
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The inconsistency between different studies reported in the literature could be due to the 
non-selective impact of pannexin inhibitors coupled with the lack of effect of agents 
that interfere with purinergic signalling. For example, the present study provided 
evidence that both mefloquine and probenecid produced non-selective inhibition of 
vascular responses at high concentrations.While the present study proved the presence 
of both pannexin1 and pannexin2 in both endothelial and smooth muscle cells of the 
PSA and the RA tissuesit does not support the ‘pannexin1 channel release ATP’ 
hypothesis, suggested by Billaud et al (2011) in thoracodorsal resistance arteries, since 
the role of P2 receptors in mediating the contractile responses was ruled out in both the 
PSA and the RA. In PSA, pannexin1 inhibitors (probenecid and mefloquine) reduced 
both the sympathetic nerve stimulation and NA-induced contractile responses, 
potentially providing evidence for the involvement of pannexin1 channels in conducting 
responses to NA in these blood vessels through mediating the α1A-adrenoceptor 
stimulated contractile responses, as opposed to the α1D–adrenoceptors suggested by 
Billaud et al (2011). Similar data was obtained in the RA, a preparation that contains 
α1D-adrenoceptors. However, no evidence was obtained for the involvement of ATP 
acting via P2 receptors in mediating either α1A-adrenoceptors-mediated vasoconstriction 
in the PSA nor α1D–adrenoceptor-mediated vasoconstriction in the RA.  
Recently, it was reported that pannexin1 had a role in facilitating vasodilator and 
anticontractile effects of the endothelium (Gaynullina et al 2014). They used 
pannexin1−/− mice as a test model for investigating the functional significance of 
pannexin1 and they concluded that endothelial function was impaired in conduit arteries 
of pannexin1 knockout mice. In particular, they demonstrated that the EDHF component 
of endothelium-dependent responses was impaired in pannexin1 knockout mice. The 
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exact mechanistic by which pannexin1 exerts its role remains speculative. However, the 
present study provided limited evidence for the involvement of pannexin channels in 
mediating the endothelium-derived hyperpolarization (EDH) response in PSA or PCA. 
Future studies 
More studies are warranted in the future to understand the mechanisms by which 
pannexin 1 channels are involved in the vasculature, as well as the mechanisms by which 
pannexin1 inhibitors exert their action. The non-selectivity issue related to the use of 
pannexin channel inhibitors could be overcome by evaluating the contractile response 
of tissue samples that do not express pannexin channels, i.e. by using pannexin1 
knockout/knockdown techniques in preference to mefloquine and probenecid. For 
instance, the involvement of pannexin1 could be ruled out through inhibiting the 
pannexin1 gene in pannexin knockout mice using RNA interference experiments to 
genetically engineer pannexin knockout mice (Mocellin and Provenzano, 2004). 
Aternatively, if RNA interference shows no reduction in responses then this will support 
the theory that the pannexin1 inhibitors we used lost selectivity at higher concentrations 
and that the reduction in responses seen was due to an alternative mechanism. 
 The involvement of pannexin1 channels in contractile responses could then only be 
confirmed if the results generated from pannexin1 inhibitors (i.e. mefloquine and 
probenecid) match those generated through RNA interference. 
The findings presented in this thesis demonstrate the pannexin1 protein is present in 
large blood vessels but the data do not support a role for ATP released via pannexin 
channels in mediating responses to NA in these blood vessels. The data using three 
different pannexin inhibitors shows that there is no evidence to suggest pannexin 
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channels are involved in mediating endothelium-dependent vasorelaxation in porcine 
splenic or coronary arteries. It is clear that new tools are required to investigate the 
physiology of pannexins. 
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